<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?subarticle pone.0233600.r001?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7259772</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0233600</article-id><article-id pub-id-type="publisher-id">PONE-D-19-27665</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Geographical Locations</subject><subj-group><subject>Africa</subject><subj-group><subject>Uganda</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Public and occupational health</subject><subj-group><subject>Preventive medicine</subject><subj-group><subject>HIV prevention</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Economics</subject><subj-group><subject>Finance</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Public and occupational health</subject><subj-group><subject>Preventive medicine</subject><subj-group><subject>HIV prevention</subject><subj-group><subject>Circumcision for HIV prevention</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>HIV epidemiology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Population Groupings</subject><subj-group><subject>Age Groups</subject><subj-group><subject>Adults</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Behavior</subject><subj-group><subject>Behavioral Economics</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Behavior</subject><subj-group><subject>Behavioral Economics</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Economics</subject><subj-group><subject>Behavioral Economics</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>A pilot randomized trial of incentive strategies to promote HIV retesting in rural Uganda</article-title><alt-title alt-title-type="running-head">Pilot trial of incentives for HIV retesting</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5860-8081</contrib-id><name><surname>Chamie</surname><given-names>Gabriel</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Ndyabakira</surname><given-names>Alex</given-names></name><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Marson</surname><given-names>Kara G.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Emperador</surname><given-names>Devy M.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kamya</surname><given-names>Moses R.</given-names></name><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Havlir</surname><given-names>Diane V.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kwarisiima</surname><given-names>Dalsone</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thirumurthy</surname><given-names>Harsha</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>University of California, San Francisco, California, United States of America</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Infectious Diseases Research Collaboration, Mbarara, Uganda</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Makerere University College of Health Sciences, Kampala, Uganda</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Makerere University Joint AIDS Program, Kampala, Uganda</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>University of Pennsylvania, Philadelphia, Pennsylvania, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>De Socio</surname><given-names>Giuseppe Vittorio</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Azienda Ospedaliera Universitaria di Perugia, ITALY</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>Gabriel.chamie@ucsf.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>15</volume><issue>5</issue><elocation-id>e0233600</elocation-id><history><date date-type="received"><day>16</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>7</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Chamie et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Chamie et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0233600.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Retesting for HIV is critical to identifying newly-infected persons and reinforcing prevention efforts among at-risk adults. Incentives can increase one-time HIV testing, but their role in promoting retesting is unknown. We sought to test feasibility and acceptability of incentive strategies, including commitment contracts, to promote HIV retesting among at-risk adults in rural Uganda.</p></sec><sec id="sec002"><title>Methods</title><p>At-risk HIV-negative adults were enrolled in a pilot trial assessing feasibility and acceptability of incentive strategies to promote HIV retesting three months after enrollment. Participants were randomized (1:1:3) to: 1) no incentive; 2) standard cash incentive (~US$4); and 3) commitment contract: participants could voluntarily make a low- or high-value deposit that would be returned with added interest (totaling ~US$4 including the deposit) upon retesting or lost if participants failed to retest. Contracts sought to promote retesting by leveraging loss aversion and addressing present bias via pre-commitment. Outcomes included acceptability of trial enrollment, contract feasibility (proportion of participants making deposits), and HIV retesting uptake.</p></sec><sec id="sec003"><title>Results</title><p>Of 130 HIV-negative eligible adults, 123 (95%) enrolled and were randomized: 74 (60%) to commitment contracts, 25 (20%) to standard incentives, and 24 (20%) to no incentive. Of contract participants, 69 (93%) made deposits. Overall, 93 (76%) participants retested for HIV: uptake was highest in the standard incentive group (22/25 [88%]) and lowest in high-value contract (26/36 [72%]) and no incentive (17/24 [71%]) groups.</p></sec><sec id="sec004"><title>Conclusion</title><p>In a randomized trial of strategies to promote HIV retesting among at-risk adults in Uganda, incentive strategies, including commitment contracts, were feasible and had high acceptability. Our findings suggest use of incentives for HIV retesting merits further comparison in a larger trial.</p></sec><sec id="sec005"><title>Trial registration</title><p>ClinicalTrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02890459">NCT:02890459</ext-link></p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000025</institution-id><institution>National Institute of Mental Health</institution></institution-wrap></funding-source><award-id>R01MH105254</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5860-8081</contrib-id><name><surname>Chamie</surname><given-names>Gabriel</given-names></name></principal-award-recipient></award-group><funding-statement>This work was supported by a grant (R01MH105254) from the National Institute of Mental Health (NIMH) at the National Institutes of Health (GC, HT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="1"/><page-count count="10"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are available at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7910/DVN/KYQPME">https://doi.org/10.7910/DVN/KYQPME</ext-link></meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are available at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7910/DVN/KYQPME">https://doi.org/10.7910/DVN/KYQPME</ext-link></p></notes></front><body><sec sec-type="intro" id="sec006"><title>Introduction</title><p>As global efforts continue to reduce HIV incidence through combination prevention approaches (such as pre-exposure prophylaxis, voluntary medical male circumcision, condoms, and universal HIV treatment as prevention), it is clear that universal HIV testing initiatives must be followed by targeted testing services that offer frequent retesting for HIV to individuals who test HIV-negative but remain at risk. Retesting of high-risk, HIV-uninfected persons is critical to identifying those recently infected with HIV, to maximize individual benefits of early antiretroviral treatment and reduce onward transmission [<xref rid="pone.0233600.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0233600.ref003" ref-type="bibr">3</xref>]. HIV retesting also offers an opportunity to reinforce behavioral and biomedical prevention among at-risk populations [<xref rid="pone.0233600.ref004" ref-type="bibr">4</xref>]. The World Health Organization recommends HIV retesting at least annually for all sexually active adults living in high HIV burden settings, including key populations at increased risk of HIV infection, noting that more frequent testing (i.e. every 3&#x02013;6 months) may be warranted based on individual risks [<xref rid="pone.0233600.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0233600.ref005" ref-type="bibr">5</xref>]. In Uganda, where the HIV prevalence among 15-49-year-old adults is 6% [<xref rid="pone.0233600.ref006" ref-type="bibr">6</xref>], the Ministry of Health (MoH) recommends retesting of HIV-negative key populations every three months [<xref rid="pone.0233600.ref007" ref-type="bibr">7</xref>].</p><p>Despite guidelines recommending retesting for HIV among at-risk adults who previously tested HIV negative, published data across multiple settings in sub-Saharan Africa, including Uganda [<xref rid="pone.0233600.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0233600.ref009" ref-type="bibr">9</xref>], suggest that retesting annually (let alone more regular intervals) occurs infrequently, with most adults who access HIV testing reporting that they have not had an HIV test in the prior year [<xref rid="pone.0233600.ref010" ref-type="bibr">10</xref>&#x02013;<xref rid="pone.0233600.ref012" ref-type="bibr">12</xref>]. In a qualitative study examining perceptions of HIV retesting prior to a universal &#x0201c;test and treat&#x0201d; intervention in South Africa, most participants expressed the view that retesting was unnecessary, particularly if a person continued to feel healthy following a prior negative HIV test [<xref rid="pone.0233600.ref013" ref-type="bibr">13</xref>]. In spite of the importance of retesting high-risk, HIV-negative adults at regular intervals to identify recent seroconversions and to reinforce prevention messaging, there are few evidence-based interventions to promote retesting among high-risk adults [<xref rid="pone.0233600.ref014" ref-type="bibr">14</xref>]. Optimal strategies to promote HIV retesting of high-risk adults in sub-Saharan Africa are unclear.</p><p>Economic incentives have been shown to promote a number of behaviors, including one-time HIV testing, in which the costs of a given behavior (e.g. stigmatization, transport costs and lost wages when accessing HIV testing) are immediate but the gains (e.g. the health benefits of antiretroviral therapy if HIV-infected or combination prevention if HIV-uninfected) may not be realized until later [<xref rid="pone.0233600.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0233600.ref016" ref-type="bibr">16</xref>]. As such, incentives may be effective in promoting retesting for HIV in people who test HIV antibody negative but remain at high-risk. However, in contrast to first-time HIV testing, interventions to promote retesting for HIV among high-risk individuals may face additional challenges, as motivation to retest may be relatively lower following a recent negative HIV test and benefits of accessing testing may be perceived as low, particularly if transportation to clinic and access to testing are costly [<xref rid="pone.0233600.ref013" ref-type="bibr">13</xref>]. Whether incentives can promote retesting for HIV in high-risk groups compared to counseling to retest alone (the current standard of care in many settings, such as Uganda [<xref rid="pone.0233600.ref007" ref-type="bibr">7</xref>]), and if so, what type of incentive approach is most effective for HIV retesting, remains unknown.</p><p>A common approach to implementing economic incentives for healthy behaviors has been to provide monetary or non-monetary rewards conditional on undertaking a desired behavior [<xref rid="pone.0233600.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0233600.ref017" ref-type="bibr">17</xref>]. However, recent studies have indicated that incentives can be made more effective by leveraging loss aversion, the tendency for losses to have a greater psychological impact on individuals than gains of comparable size [<xref rid="pone.0233600.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0233600.ref019" ref-type="bibr">19</xref>]. Thus, avoiding a monetary loss (such as a small financial penalty for not exercising) tends to be more motivating than a gain (such as a small financial gain for exercising) of equal amount [<xref rid="pone.0233600.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0233600.ref021" ref-type="bibr">21</xref>]. Individuals may also be aware of their own tendency towards present-biased decision-making: the tendency to place disproportionate weight on present (or short-term) rather than future (or long-term) costs and benefits [<xref rid="pone.0233600.ref022" ref-type="bibr">22</xref>]. One approach to putting loss aversion into practice, and to actively counter-acting present bias, is a &#x0201c;commitment contract&#x0201d; in which individuals interested in achieving a goal (such as smoking cessation, weight loss, or retesting for HIV) commit to the goal in advance by making a financial deposit, and then risk losing the deposit if they do not achieve the goal [<xref rid="pone.0233600.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0233600.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0233600.ref024" ref-type="bibr">24</xref>]. Efforts to implement commitment contracts in middle- and high-income countries have generally found that though there may be low uptake of commitment contracts, effectiveness can be high among those who agree to make a deposit [<xref rid="pone.0233600.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0233600.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0233600.ref025" ref-type="bibr">25</xref>]. However, to our knowledge, no incentive-based approaches in sub-Saharan Africa have attempted to leverage loss aversion for behavior change through commitment contracts, given legitimate concerns regarding acceptability and feasibility. The aim of this study was to assess the feasibility and acceptability of various incentive strategies, including commitment contracts that required a baseline deposit, to promote HIV retesting among at-risk adults in rural Uganda.</p></sec><sec sec-type="materials|methods" id="sec007"><title>Methods</title><p>We recruited adults at increased risk of HIV compared to the general population from a community in rural, southwestern Uganda (NCT:02890459). Study staff first met with local health officials and community representatives to identify venues frequented by adults considered at increased risk of HIV, due to attendance at bars associated with transactional sex, participation in sex work, high mobility to and from the community, or trading center work [<xref rid="pone.0233600.ref007" ref-type="bibr">7</xref>]. The venues identified included bars, motorcycle taxi stages, a hair salons, a restaurant, a primary care clinic waiting room, and a local trading center. Study staff then visited these venues to distribute recruitment cards inviting adults to come to the local government-run clinic for a free health evaluation that included HIV testing. Adults were asked to bring the recruitment cards in order to receive a one-time incentive payment of 15,000 Ugandan Shillings (USh; or ~US$4 in 2017) for the health evaluation and to consider joining a study. Adults who presented to the clinic with recruitment cards underwent rapid HIV antibody testing with the Alere Determine<sup>TM</sup> HIV-1/2 Ag/Ab Combo, followed by the Chembio HIV 1/2 STAT-PAK<sup>&#x000ae;</sup> and SD Bioline HIV-1/2 assays for confirmation of Determine-positive results according to Uganda MoH guidelines [<xref rid="pone.0233600.ref007" ref-type="bibr">7</xref>], as well as screening for hypertension and diabetes.</p><p>Enrollment was offered to eligible adults, 18&#x02013;59 years of age, who presented with recruitment cards, tested negative for HIV, and had no intention of moving away from the community within three months. Eligible adults who provided informed, written consent underwent a baseline questionnaire: a 62-question survey developed by study investigators and administered by study staff to understand participant demographics, socioeconomic status, HIV risk behaviors, prior HIV testing behavior and testing preferences (see Supporting Information: S3). The questionnaire was followed by randomization (by block randomization, with block size = 10 and allocation sequence computer-generated prior to initiation of trial enrollment by study investigators). Participants chose a sealed envelope from several offered by study staff to unveil study group allocation to one of three groups (1:1:3) to promote HIV retesting within 2&#x02013;3 months: a) no incentive (control); b) a standard, gain-framed (i.e. presented as a &#x0201c;gain&#x0201d; or bonus) cash incentive (15,000 USh); and c) a commitment contract, in which participants could voluntarily make a deposit that would be returned with added interest (totaling 15,000 USh) upon retesting. The contract group had low- and high-value deposit arms (2,500 USh = US$0.71, or 5,000 USh = US$1.42) in order to assess how the initial deposit amount affected uptake of the commitment contract. Participants in the contract groups were told the deposits were completely voluntary (i.e. there was no requirement to make a deposit) and that the deposits would be lost if they did not return for HIV retesting between 2&#x02013;3 months following randomization. All groups received counseling encouraging retesting for HIV three months after enrollment, consistent with Uganda MoH guidelines for high-risk populations [<xref rid="pone.0233600.ref007" ref-type="bibr">7</xref>], at the same clinical site where baseline testing occurred. Outcomes included acceptability of trial participation (defined as the number of eligible adults that agreed to continue participating in the pilot trial following randomization) among eligible adults, feasibility of commitment contracts for HIV retesting (defined as the proportion of contract group participants who made a baseline deposit), HIV retesting uptake 2&#x02013;3 months following enrollment (to determine likely effect sizes), and HIV seroconversion.</p><sec id="sec008"><title>Statistical analysis</title><p>Descriptive statistics were used to present baseline characteristics, including means, standard deviations (SD), medians, and interquartile ranges (IQR). Outcomes were calculated using exact methods to obtain proportions with binomial confidence intervals (CI). As this was a pilot study, we determined sample size based on an <italic>a priori</italic> interest in feasibility of commitment contracts in approximately 70 adults rather than using power calculations, in preparation for a larger trial of the effectiveness of incentive strategies to promote HIV retesting.</p><p>All participants provided written informed consent in their preferred language (English or Runyankole, the local language in the region). The Makerere University School of Medicine Research and Ethics Committee (Uganda), the Uganda National Council for Science and Technology, and the University of California San Francisco (UCSF) Committee on Human Research [<xref rid="pone.0233600.ref026" ref-type="bibr">26</xref>] approved the study protocol. The UCSF Committee on Human Research served as the institutional review board of record for investigators from the University of Pennsylvania [<xref rid="pone.0233600.ref026" ref-type="bibr">26</xref>].</p></sec></sec><sec sec-type="results" id="sec009"><title>Results</title><p>From August 8&#x02013;22 2017, study staff distributed 164 recruitment cards at 26 venues frequented by adults considered high-risk for HIV: bars, sites of commercial sex work (i.e. a hair salon and a restaurant), a trading centers with mobile vendors, a primary care clinic waiting room, and transportation hubs (i.e. truck stops and motorcycle taxi stages). Over eight days following recruitment card distribution, 153 (93%) adults presented with recruitment cards and tested for HIV at the local government-run health center. Of those tested, median age was 31 years (IQR: 26&#x02013;37), 113 (74%) were men, and 23 (15%) tested HIV-positive. HIV positivity varied by recruitment site: e.g. 0% (0/11) at the clinic waiting room, 11% (11/99) at transport hubs, 13% (4/21) at trading centers, 54% (7/13) at bars/sites of commercial sex work, and 11% (1/9) at storefronts associated with informal sex work.</p><p>Of 130 HIV-uninfected, eligible adults, 123 (95%) enrolled in the trial and were randomized (<xref ref-type="fig" rid="pone.0233600.g001">Fig 1</xref>): 74 (60%) to commitment contracts (38 and 36 in low- and high-value deposits, respectively), 25 (20%) to gain-framed incentives, and 24 (20%) to no incentive. Among commitment contract participants, 69/74 (93%; 95% confidence interval [CI]: 85&#x02013;98%) adults provided an initial deposit: 36/38 (95%) in low-value and 33/36 (92%) in high-value groups (<xref rid="pone.0233600.t001" ref-type="table">Table 1</xref>). Of the five participants who declined to deposit, reasons given included fear of losing the deposit (N = 2), and inability to afford the deposit amount (N = 3). Among the no incentive group and the gain-framed incentive group, 96% (23/24) and 92% (23/25) reported a willingness to provide a commitment contract deposit if offered, respectively.</p><fig id="pone.0233600.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0233600.g001</object-id><label>Fig 1</label><caption><title>Pilot trial CONSORT diagram, indicating the number of participants screened, enrolled, randomized with allocation to study arm, lost to follow up, and assessed at trial completion.</title></caption><graphic xlink:href="pone.0233600.g001"/></fig><table-wrap id="pone.0233600.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0233600.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics and HIV retesting uptake among at-risk adults (N = 123) enrolled in a pilot, randomized-controlled trial of incentives strategies to promote retesting for HIV three months after an initial negative HIV antibody test.</title></caption><alternatives><graphic id="pone.0233600.t001g" xlink:href="pone.0233600.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="center" rowspan="1" colspan="1">No Incentive (Control)</th><th align="center" rowspan="1" colspan="1">Gain-framed Incentive</th><th align="center" rowspan="1" colspan="1">Commitment Contract: $0.71 deposit</th><th align="center" rowspan="1" colspan="1">Commitment Contract: $1.42 deposit</th></tr><tr><th align="center" rowspan="1" colspan="1">(N = 24)</th><th align="center" rowspan="1" colspan="1">(N = 25)</th><th align="center" rowspan="1" colspan="1">(N = 38)</th><th align="center" rowspan="1" colspan="1">(N = 36)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Age</bold>: median (IQR)</td><td align="center" rowspan="1" colspan="1">30 (28&#x02013;36)</td><td align="center" rowspan="1" colspan="1">30 (25&#x02013;37)</td><td align="center" rowspan="1" colspan="1">31 (25&#x02013;37)</td><td align="center" rowspan="1" colspan="1">31 (25&#x02013;35)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Female</bold>: N (%)</td><td align="center" rowspan="1" colspan="1">5 (21%)</td><td align="center" rowspan="1" colspan="1">8 (32%)</td><td align="center" rowspan="1" colspan="1">7 (18%)</td><td align="center" rowspan="1" colspan="1">12 (33%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Daily wage (2017 US Dollars)</bold>: mean (standard deviation (SD))</td><td align="center" rowspan="1" colspan="1">$3.80 (3.64)</td><td align="center" rowspan="1" colspan="1">$2.59 (1.67)</td><td align="center" rowspan="1" colspan="1">$2.64 (1.92)</td><td align="center" rowspan="1" colspan="1">$2.45 (1.95)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Attended Secondary school:</bold> N (%)</td><td align="center" rowspan="1" colspan="1">9 (39)</td><td align="center" rowspan="1" colspan="1">9 (38)</td><td align="center" rowspan="1" colspan="1">4 (11)</td><td align="center" rowspan="1" colspan="1">12 (36)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Married:</bold> N (%)</td><td align="center" rowspan="1" colspan="1">18 (75)</td><td align="center" rowspan="1" colspan="1">18 (72)</td><td align="center" rowspan="1" colspan="1">28 (74)</td><td align="center" rowspan="1" colspan="1">27 (75)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Tested for HIV &#x02264; one time in past 12 months, by self-report</bold>: N (%)</td><td align="center" rowspan="1" colspan="1">10 (42%)</td><td align="center" rowspan="1" colspan="1">8 (32%)</td><td align="center" rowspan="1" colspan="1">13 (34%)</td><td align="center" rowspan="1" colspan="1">7 (19%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Self-reported having sex partner outside of primary relationship in past 12 months</bold>: N (%)</td><td align="center" rowspan="1" colspan="1">7 (29%)</td><td align="center" rowspan="1" colspan="1">13 (52%)</td><td align="center" rowspan="1" colspan="1">21 (55%)</td><td align="center" rowspan="1" colspan="1">19 (53%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Self-reported number sex partners in past 12 months</bold>: mean (SD)</td><td align="center" rowspan="1" colspan="1">4.6 (2.8)</td><td align="center" rowspan="1" colspan="1">2.8 (1.7)</td><td align="center" rowspan="1" colspan="1">8.5 (20.8)</td><td align="center" rowspan="1" colspan="1">2.9 (4.6)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Received or paid money in exchange for sex in past 12 months, by self-report</bold>: N (%)</td><td align="center" rowspan="1" colspan="1">4 (17%)</td><td align="center" rowspan="1" colspan="1">10 (40%)</td><td align="center" rowspan="1" colspan="1">12 (32%)</td><td align="center" rowspan="1" colspan="1">6 (17%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>No condom use when receiving or paying money in exchange for sex in past 12 months, by self-report</bold></td><td align="center" rowspan="1" colspan="1">2/4</td><td align="center" rowspan="1" colspan="1">4/10</td><td align="center" rowspan="1" colspan="1">4/12</td><td align="center" rowspan="1" colspan="1">5/6</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Deposit made to commitment contract:</bold> N (%; [95% CI])</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">36 (95% [82&#x02013;99%])</td><td align="center" rowspan="1" colspan="1">33 (92% [78&#x02013;98%])</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Reported willingness to deposit, if offered opportunity:</bold> N (%; [95% CI])</td><td align="center" rowspan="1" colspan="1">23 (96% [79&#x02013;100%])</td><td align="center" rowspan="1" colspan="1">23 (92% [74&#x02013;99%])</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>HIV Retesting 2&#x02013;3 months following randomization:</bold> N (%; [95% CI])</td><td align="center" rowspan="1" colspan="1">17 (71% [49&#x02013;87%])</td><td align="center" rowspan="1" colspan="1">22 (88% [69&#x02013;97%])</td><td align="center" rowspan="1" colspan="1">28 (74% [57&#x02013;87%])</td><td align="center" rowspan="1" colspan="1">26 (72% [55&#x02013;86%])</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>IQR = Interquartile Range; N/A = Not applicable; CI = Confidence Interval.</p></fn></table-wrap-foot></table-wrap><p>Overall, 93/123 (76%; 95% CI: 67&#x02013;83%) adults retested for HIV 2&#x02013;3 months following their initial HIV-negative test. Retesting uptake was highest in the standard, gain-framed incentive group (88%) and lowest in high-value contract (72%) and no incentive (71%) groups (<xref rid="pone.0233600.t001" ref-type="table">Table 1</xref>). Among contract participants who made a deposit, HIV retesting was 78% in low- and 76% in high-value groups. As noted in the Methods, this pilot trial was not powered to detect statistically significant differences in retesting between arms. No seroconversions were observed.</p></sec><sec sec-type="conclusions" id="sec010"><title>Discussion</title><p>In a pilot randomized controlled trial of financial incentives to promote retesting for HIV among at-risk adults in rural Uganda, incentive strategies, including commitment contracts with voluntary deposits, were feasible and had high (95%) acceptability. In this first attempt to implement commitment contracts to promote an HIV prevention behavior in sub-Saharan Africa, the large majority of participants (&#x0003e;90%) made a deposit committing to retesting in the future when offered the opportunity. Our findings suggest the use of incentives, including commitment contracts, for HIV retesting is feasible and merits further study in a larger trial.</p><p>Commitment contracts are an innovative and potentially low-cost approach to incentivizing behavior change that leverage loss aversion, the tendency of individuals to be more motivated by a loss than a gain of equal value when making decisions, as well as voluntary pre-commitment to overcome present bias [<xref rid="pone.0233600.ref018" ref-type="bibr">18</xref>]. While voluntary commitment contracts have been put into practice for behaviors such as smoking cessation or weight loss in high- and middle-income countries [<xref rid="pone.0233600.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0233600.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0233600.ref025" ref-type="bibr">25</xref>], to our knowledge, they have not been attempted in low-income countries where individuals&#x02019; ability to make deposits may be limited by poverty. We sought to overcome these obstacles in a pragmatic manner by offering all participants a standard incentive for their initial HIV test, and then providing contract participants an opportunity to voluntarily deposit part of this initial incentive (or &#x0201c;endowment&#x0201d;) if they wished to commit to HIV retesting in the future. This approach of offering an opportunity to deposit part of this initial incentive also addressed a limitation observed in commitment contract programs in high- and mid-income countries, where a relatively small percentage of those offered such contracts actually make a deposit [<xref rid="pone.0233600.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0233600.ref023" ref-type="bibr">23</xref>]. The high rates of deposits made by participants in our study are encouraging in this regard and may indicate a clear understanding of the benefits of HIV retesting among high-risk individuals. Indeed, commitment contracts may be ideal for use by people who desire a long-term goal but need an additional &#x0201c;nudge&#x0201d; to achieve the goal. Alternatively, the high deposit rates observed could indicate that the deposit amount was too low&#x02013;i.e. the loss of the deposit was a risk worth taking even if the desire to retest in the future was not strong. Though this latter explanation is possible, the deposit amounts represented between 25&#x02013;50% of the average daily wage in the contract groups, suggesting the deposits were not trivial. Future studies of commitment contracts for HIV retesting may need to determine the optimal balance between deposit amounts that are acceptable and of sufficient value to generate loss aversion.</p><p>Our findings add to a growing literature on the use of strategies informed by behavioral economics, including financial incentives and opt-out provider-initiated testing and counseling, to promote HIV testing and other HIV-related behaviors and outcomes. The effectiveness of these strategies when studied in randomized trials has varied [<xref rid="pone.0233600.ref027" ref-type="bibr">27</xref>]. Examples of effective strategies have included gain-framed incentives to promote voluntary medical male circumcision (VMMC) in Kenya [<xref rid="pone.0233600.ref028" ref-type="bibr">28</xref>] and self-testing among male partners of women attending antenatal care in Malawi [<xref rid="pone.0233600.ref029" ref-type="bibr">29</xref>], as well as lotteries to promote HIV testing of adolescents in Zimbabwe [<xref rid="pone.0233600.ref030" ref-type="bibr">30</xref>], HIV testing among men in Uganda [<xref rid="pone.0233600.ref009" ref-type="bibr">9</xref>], and negative sexually transmitted infection screening results in Lesotho [<xref rid="pone.0233600.ref031" ref-type="bibr">31</xref>]. However, some studies have found financial incentives to be ineffective compared to no incentive control conditions for other HIV-related outcomes, such as achieving or maintaining viral suppression in Uganda [<xref rid="pone.0233600.ref032" ref-type="bibr">32</xref>] or decreasing engagement in high-risk sexual activity among men in Malawi [<xref rid="pone.0233600.ref033" ref-type="bibr">33</xref>]. The findings from this pilot trial add to this literature, by demonstrating that deposit contracts can be acceptable and feasible for promoting HIV retesting and might also be feasible for other health behaviors. Future research could address knowledge gaps in effectiveness of commitment contracts or incentives for retesting and explore barriers and facilitators to retesting among high-risk adults after a prior negative HIV test.</p><p>Our study has several limitations. First, our pilot trial was designed to test acceptability and feasibility of various incentive approaches, particularly commitment contracts, for HIV retesting and as such, was not powered to detect differences in retesting uptake by study arm or seroconversions. Second, although retesting uptake was high (&#x0003e;70%) in all groups, including the control group (71%), participants in the control group may have anticipated a reward upon retesting due to the receipt of the initial incentive at enrollment, despite our efforts to explain the absence of incentives for retesting. In future studies with more than one retesting opportunity, we suspect HIV retesting might decline over time when incentives are not offered, as has been observed with other repeated health behaviors such as smoking cessation [<xref rid="pone.0233600.ref019" ref-type="bibr">19</xref>]. In addition, whether participants who agree to commitment contracts would agree to a deposit without an initial endowment remains unknown. Third, our commitment contract group included &#x0201c;interest&#x0201d; on the initial deposit, and as such combined loss aversion with an additional gain. The interest was included to avoid a penalty for making deposits but may also explain the high acceptability of commitment contracts in this pilot. Fourth, no HIV seroconversions were observed in this study, possibly suggesting that we did not reach a high-risk population that needed frequent (i.e. every 3-month vs. annual) HIV retesting. However, participants reported high-risk sexual behavior including sex outside of a primary partnership and paying/receiving money in exchange for sex, in many cases without condom use. These observations, along with the high prevalence of HIV among adults screened (15%, in a setting where the adult HIV prevalence is 6.5% among the general population [<xref rid="pone.0233600.ref008" ref-type="bibr">8</xref>]), suggest our recruitment strategy selected for high-risk individuals.</p></sec><sec sec-type="conclusions" id="sec011"><title>Conclusion</title><p>As reported rates of &#x0201c;ever&#x0201d; having tested for HIV increase in sub-Saharan Africa and the number of first-time testers declines [<xref rid="pone.0233600.ref034" ref-type="bibr">34</xref>], identifying interventions to promote retesting in persons at increased risk for HIV becomes a greater priority. Our pilot data suggest that economic incentives, including commitment contracts, are an acceptable and feasible method to promote HIV retesting that merit further evaluation.</p></sec><sec sec-type="supplementary-material" id="sec012"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0233600.s001"><label>S1 Data</label><caption><title>Deidentified study dataset.</title><p>(DOC)</p></caption><media xlink:href="pone.0233600.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0233600.s002"><label>S2 Data</label><caption><title>Version of the study protocol that was in use at the time of initial participant enrollment in this study.</title><p>(DOCX)</p></caption><media xlink:href="pone.0233600.s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0233600.s003"><label>S1 File</label><caption><p>(PDF)</p></caption><media xlink:href="pone.0233600.s003.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank the residents of the study communities for their generous participation in our study. We gratefully acknowledge the contributions of Jane Kabami and Stella Kabageni from the Infectious Diseases Research Collaboration in Mbarara, Uganda.</p></ack><ref-list><title>References</title><ref id="pone.0233600.ref001"><label>1</label><mixed-citation publication-type="journal"><collab>Group TAS</collab>, <name><surname>Danel</surname><given-names>C</given-names></name>, <name><surname>Moh</surname><given-names>R</given-names></name>, <name><surname>Gabillard</surname><given-names>D</given-names></name>, <name><surname>Badje</surname><given-names>A</given-names></name>, <name><surname>Le Carrou</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa</article-title>. <source>The New England journal of medicine</source>. <year>2015</year>;<volume>373</volume>(<issue>9</issue>):<fpage>808</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">26193126</pub-id></mixed-citation></ref><ref id="pone.0233600.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Lundgren</surname><given-names>JD</given-names></name>, <name><surname>Babiker</surname><given-names>AG</given-names></name>, <name><surname>Gordin</surname><given-names>F</given-names></name>, <name><surname>Emery</surname><given-names>S</given-names></name>, <name><surname>Grund</surname><given-names>B</given-names></name>, <name><surname>Sharma</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection</article-title>. <source>The New England journal of medicine</source>. <year>2015</year>;<volume>373</volume>(<issue>9</issue>):<fpage>795</fpage>&#x02013;<lpage>807</lpage>.<pub-id pub-id-type="pmid">26192873</pub-id></mixed-citation></ref><ref id="pone.0233600.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>MS</given-names></name>, <name><surname>Chen</surname><given-names>YQ</given-names></name>, <name><surname>McCauley</surname><given-names>M</given-names></name>, <name><surname>Gamble</surname><given-names>T</given-names></name>, <name><surname>Hosseinipour</surname><given-names>MC</given-names></name>, <name><surname>Kumarasamy</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Prevention of HIV-1 infection with early antiretroviral therapy</article-title>. <source>The New England journal of medicine</source>. <year>2011</year>;<volume>365</volume>(<issue>6</issue>):<fpage>493</fpage>&#x02013;<lpage>505</lpage>.<pub-id pub-id-type="pmid">21767103</pub-id></mixed-citation></ref><ref id="pone.0233600.ref004"><label>4</label><mixed-citation publication-type="journal"><collab>World Health Organization</collab>. <source>Policy Brief: Consolidated Guidelines on HIV Testing Services for a Changing Epidemic</source>. <year>2019</year>.</mixed-citation></ref><ref id="pone.0233600.ref005"><label>5</label><mixed-citation publication-type="other">World Health Organization (WHO) Consolidated Guidelines on HIV Testing Services Geneva, Switzerland2015.</mixed-citation></ref><ref id="pone.0233600.ref006"><label>6</label><mixed-citation publication-type="other">Uganda HIV/AIDS Country Progress Report July 2016-June 2017. Accessible at: <ext-link ext-link-type="uri" xlink:href="https://www.unaids.org/sites/default/files/country/documents/UGA_2018_countryreport.pdf">https://www.unaids.org/sites/default/files/country/documents/UGA_2018_countryreport.pdf</ext-link>. Last accessed August 26, 2019. Uganda2017.</mixed-citation></ref><ref id="pone.0233600.ref007"><label>7</label><mixed-citation publication-type="other">Uganda Ministry of Health: Consolidated Guidelines for Prevention and Treatment of HIV in Uganda. 2016.</mixed-citation></ref><ref id="pone.0233600.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Chamie</surname><given-names>G</given-names></name>, <name><surname>Clark</surname><given-names>TD</given-names></name>, <name><surname>Kabami</surname><given-names>J</given-names></name>, <name><surname>Kadede</surname><given-names>K</given-names></name>, <name><surname>Ssemmondo</surname><given-names>E</given-names></name>, <name><surname>Steinfeld</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study</article-title>. <source>Lancet HIV</source>. <year>2016</year>;<volume>3</volume>(<issue>3</issue>):<fpage>e111</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26939734</pub-id></mixed-citation></ref><ref id="pone.0233600.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Chamie</surname><given-names>G</given-names></name>, <name><surname>Schaffer</surname><given-names>EM</given-names></name>, <name><surname>Ndyabakira</surname><given-names>A</given-names></name>, <name><surname>Emperador</surname><given-names>DM</given-names></name>, <name><surname>Kwarisiima</surname><given-names>D</given-names></name>, <name><surname>Camlin</surname><given-names>CS</given-names></name>, <etal>et al</etal>
<article-title>Comparative effectiveness of novel nonmonetary incentives to promote HIV testing</article-title>. <source>AIDS (London, England)</source>. <year>2018</year>;<volume>32</volume>(<issue>11</issue>):<fpage>1443</fpage>&#x02013;<lpage>51</lpage>.</mixed-citation></ref><ref id="pone.0233600.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Cawley</surname><given-names>C</given-names></name>, <name><surname>Wringe</surname><given-names>A</given-names></name>, <name><surname>Isingo</surname><given-names>R</given-names></name>, <name><surname>Mtenga</surname><given-names>B</given-names></name>, <name><surname>Clark</surname><given-names>B</given-names></name>, <name><surname>Marston</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Low rates of repeat HIV testing despite increased availability of antiretroviral therapy in rural Tanzania: findings from 2003&#x02013;2010</article-title>. <source>PLoS ONE</source>. <year>2013</year>;<volume>8</volume>(<issue>4</issue>):<fpage>e62212</fpage>.<pub-id pub-id-type="pmid">23626791</pub-id></mixed-citation></ref><ref id="pone.0233600.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Regan</surname><given-names>S</given-names></name>, <name><surname>Losina</surname><given-names>E</given-names></name>, <name><surname>Chetty</surname><given-names>S</given-names></name>, <name><surname>Giddy</surname><given-names>J</given-names></name>, <name><surname>Walensky</surname><given-names>RP</given-names></name>, <name><surname>Ross</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Factors associated with self-reported repeat HIV testing after a negative result in Durban, South Africa</article-title>. <source>PLoS ONE</source>. <year>2013</year>;<volume>8</volume>(<issue>4</issue>):<fpage>e62362</fpage>.<pub-id pub-id-type="pmid">23626808</pub-id></mixed-citation></ref><ref id="pone.0233600.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Kranzer</surname><given-names>K</given-names></name>, <name><surname>van Schaik</surname><given-names>N</given-names></name>, <name><surname>Karmue</surname><given-names>U</given-names></name>, <name><surname>Middelkoop</surname><given-names>K</given-names></name>, <name><surname>Sebastian</surname><given-names>E</given-names></name>, <name><surname>Lawn</surname><given-names>SD</given-names></name>, <etal>et al</etal>
<article-title>High prevalence of self-reported undiagnosed HIV despite high coverage of HIV testing: a cross-sectional population based sero-survey in South Africa</article-title>. <source>PLoS ONE</source>. <year>2011</year>;<volume>6</volume>(<issue>9</issue>):<fpage>e25244</fpage>.<pub-id pub-id-type="pmid">21969875</pub-id></mixed-citation></ref><ref id="pone.0233600.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Orne-Gliemann</surname><given-names>J</given-names></name>, <name><surname>Zuma</surname><given-names>T</given-names></name>, <name><surname>Chikovore</surname><given-names>J</given-names></name>, <name><surname>Gillespie</surname><given-names>N</given-names></name>, <name><surname>Grant</surname><given-names>M</given-names></name>, <name><surname>Iwuji</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Community perceptions of repeat HIV-testing: experiences of the ANRS 12249 Treatment as Prevention trial in rural South Africa</article-title>. <source>AIDS Care</source>. <year>2016</year>;<volume>28</volume>
<issue>Suppl 3</issue>:<fpage>14</fpage>&#x02013;<lpage>23</lpage>.</mixed-citation></ref><ref id="pone.0233600.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Paschen-Wolff</surname><given-names>MM</given-names></name>, <name><surname>Restar</surname><given-names>A</given-names></name>, <name><surname>Gandhi</surname><given-names>AD</given-names></name>, <name><surname>Serafino</surname><given-names>S</given-names></name>, <name><surname>Sandfort</surname><given-names>T</given-names></name>. <article-title>A Systematic Review of Interventions that Promote Frequent HIV Testing</article-title>. <source>AIDS Behav</source>. <year>2019</year>;<volume>23</volume>(<issue>4</issue>):<fpage>860</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">30707329</pub-id></mixed-citation></ref><ref id="pone.0233600.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Thornton</surname><given-names>RL</given-names></name>. <article-title>The Demand for, and Impact of, Learning HIV Status</article-title>. <source>Am Econ Rev</source>. <year>2008</year>;<volume>98</volume>(<issue>5</issue>):<fpage>1829</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">21687831</pub-id></mixed-citation></ref><ref id="pone.0233600.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>R</given-names></name>, <name><surname>Cui</surname><given-names>RR</given-names></name>, <name><surname>Muessig</surname><given-names>KE</given-names></name>, <name><surname>Thirumurthy</surname><given-names>H</given-names></name>, <name><surname>Tucker</surname><given-names>JD</given-names></name>. <article-title>Incentivizing HIV/STI Testing: A Systematic Review of the Literature</article-title>. <source>AIDS Behav</source>. <year>2013</year>.</mixed-citation></ref><ref id="pone.0233600.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Volpp</surname><given-names>KG</given-names></name>, <name><surname>Pauly</surname><given-names>MV</given-names></name>, <name><surname>Loewenstein</surname><given-names>G</given-names></name>, <name><surname>Bangsberg</surname><given-names>D</given-names></name>. <article-title>P4P4P: an agenda for research on pay-for-performance for patients</article-title>. <source>Health Aff (Millwood)</source>. <year>2009</year>;<volume>28</volume>(<issue>1</issue>):<fpage>206</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">19124872</pub-id></mixed-citation></ref><ref id="pone.0233600.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Halpern</surname><given-names>SD</given-names></name>, <name><surname>Asch</surname><given-names>DA</given-names></name>, <name><surname>Volpp</surname><given-names>KG</given-names></name>. <article-title>Commitment contracts as a way to health</article-title>. <source>BMJ (Clinical research ed</source>. <year>2012</year>;<volume>344</volume>:<fpage>e522</fpage>.</mixed-citation></ref><ref id="pone.0233600.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Halpern</surname><given-names>SD</given-names></name>, <name><surname>French</surname><given-names>B</given-names></name>, <name><surname>Small</surname><given-names>DS</given-names></name>, <name><surname>Saulsgiver</surname><given-names>K</given-names></name>, <name><surname>Harhay</surname><given-names>MO</given-names></name>, <name><surname>Audrain-McGovern</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Randomized trial of four financial-incentive programs for smoking cessation</article-title>. <source>The New England journal of medicine</source>. <year>2015</year>;<volume>372</volume>(<issue>22</issue>):<fpage>2108</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">25970009</pub-id></mixed-citation></ref><ref id="pone.0233600.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Kahneman</surname><given-names>D</given-names></name>, <name><surname>Tversky</surname><given-names>A</given-names></name>. <article-title>Prospect theory: an analysis of decision under risk</article-title>. <source>Econometrica</source>. <year>1979</year>;<volume>47</volume>(<issue>2</issue>):<fpage>263</fpage>&#x02013;<lpage>91</lpage>.</mixed-citation></ref><ref id="pone.0233600.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Patel</surname><given-names>MS</given-names></name>, <name><surname>Asch</surname><given-names>DA</given-names></name>, <name><surname>Rosin</surname><given-names>R</given-names></name>, <name><surname>Small</surname><given-names>DS</given-names></name>, <name><surname>Bellamy</surname><given-names>SL</given-names></name>, <name><surname>Heuer</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Framing Financial Incentives to Increase Physical Activity Among Overweight and Obese Adults: A Randomized, Controlled Trial</article-title>. <source>Annals of internal medicine</source>. <year>2016</year>;<volume>164</volume>(<issue>6</issue>):<fpage>385</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">26881417</pub-id></mixed-citation></ref><ref id="pone.0233600.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>O'Donoghue</surname><given-names>T</given-names></name>, <name><surname>Rabin</surname><given-names>M</given-names></name>. <article-title>Doing it now or later</article-title>. <source>American Economic Review</source>. <year>1999</year>;<volume>89</volume>(<issue>1</issue>):<fpage>103</fpage>&#x02013;<lpage>24</lpage>.</mixed-citation></ref><ref id="pone.0233600.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Gin&#x000e9;</surname><given-names>X</given-names></name>, <name><surname>Karlan</surname><given-names>D</given-names></name>, <name><surname>Zinman</surname><given-names>J</given-names></name>. <article-title>Put Your Money Where Your Butt Is: A Commitment Contract for Smoking Cessation. American Economics Journal</article-title>: <source>Applied Economics</source>. <year>2010</year>;<volume>2</volume>:<fpage>213</fpage>&#x02013;<lpage>35</lpage>.</mixed-citation></ref><ref id="pone.0233600.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Volpp</surname><given-names>KG</given-names></name>, <name><surname>John</surname><given-names>LK</given-names></name>, <name><surname>Troxel</surname><given-names>AB</given-names></name>, <name><surname>Norton</surname><given-names>L</given-names></name>, <name><surname>Fassbender</surname><given-names>J</given-names></name>, <name><surname>Loewenstein</surname><given-names>G</given-names></name>. <article-title>Financial incentive-based approaches for weight loss: a randomized trial</article-title>. <source>JAMA</source>. <year>2008</year>;<volume>300</volume>(<issue>22</issue>):<fpage>2631</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">19066383</pub-id></mixed-citation></ref><ref id="pone.0233600.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>White</surname><given-names>JS</given-names></name>, <name><surname>Dow</surname><given-names>WH</given-names></name>, <name><surname>Rungruanghiranya</surname><given-names>S</given-names></name>. <article-title>Commitment contracts and team incentives: a randomized controlled trial for smoking cessation in Thailand</article-title>. <source>Am J Prev Med</source>. <year>2013</year>;<volume>45</volume>(<issue>5</issue>):<fpage>533</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">24139765</pub-id></mixed-citation></ref><ref id="pone.0233600.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Ribamar Costa</surname><given-names>J</given-names><suffix>Jr</suffix></name>., <name><surname>Abizaid</surname><given-names>A</given-names></name>, <name><surname>Sousa</surname><given-names>A</given-names></name>, <name><surname>Siqueira</surname><given-names>D</given-names></name>, <name><surname>Chamie</surname><given-names>D</given-names></name>, <name><surname>Feres</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Serial greyscale and radiofrequency intravascular ultrasound assessment of plaque modification and vessel geometry at proximal and distal edges of bare metal and first-generation drug-eluting stents</article-title>. <source>EuroIntervention</source>. <year>2012</year>;<volume>8</volume>(<issue>2</issue>):<fpage>225</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">22717925</pub-id></mixed-citation></ref><ref id="pone.0233600.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Thirumurthy</surname><given-names>H</given-names></name>, <name><surname>Asch</surname><given-names>DA</given-names></name>, <name><surname>Volpp</surname><given-names>KG</given-names></name>. <article-title>The Uncertain Effect of Financial Incentives to Improve Health Behaviors</article-title>. <source>JAMA</source>. <year>2019</year>;<volume>321</volume>(<issue>15</issue>):<fpage>1451</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">30907936</pub-id></mixed-citation></ref><ref id="pone.0233600.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Thirumurthy</surname><given-names>H</given-names></name>, <name><surname>Masters</surname><given-names>SH</given-names></name>, <name><surname>Rao</surname><given-names>S</given-names></name>, <name><surname>Bronson</surname><given-names>MA</given-names></name>, <name><surname>Lanham</surname><given-names>M</given-names></name>, <name><surname>Omanga</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Effect of providing conditional economic compensation on uptake of voluntary medical male circumcision in Kenya: a randomized clinical trial</article-title>. <source>Jama</source>. <year>2014</year>;<volume>312</volume>(<issue>7</issue>):<fpage>703</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">25042290</pub-id></mixed-citation></ref><ref id="pone.0233600.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Choko</surname><given-names>AT</given-names></name>, <name><surname>Corbett</surname><given-names>EL</given-names></name>, <name><surname>Stallard</surname><given-names>N</given-names></name>, <name><surname>Maheswaran</surname><given-names>H</given-names></name>, <name><surname>Lepine</surname><given-names>A</given-names></name>, <name><surname>Johnson</surname><given-names>CC</given-names></name>, <etal>et al</etal>
<article-title>HIV self-testing alone or with additional interventions, including financial incentives, and linkage to care or prevention among male partners of antenatal care clinic attendees in Malawi: An adaptive multi-arm, multi-stage cluster randomised trial</article-title>. <source>PLoS medicine</source>. <year>2019</year>;<volume>16</volume>(<issue>1</issue>):<fpage>e1002719</fpage>.<pub-id pub-id-type="pmid">30601823</pub-id></mixed-citation></ref><ref id="pone.0233600.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Kranzer</surname><given-names>K</given-names></name>, <name><surname>Simms</surname><given-names>V</given-names></name>, <name><surname>Bandason</surname><given-names>T</given-names></name>, <name><surname>Dauya</surname><given-names>E</given-names></name>, <name><surname>McHugh</surname><given-names>G</given-names></name>, <name><surname>Munyati</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Economic incentives for HIV testing by adolescents in Zimbabwe: a randomised controlled trial</article-title>. <source>Lancet HIV</source>. <year>2017</year>.</mixed-citation></ref><ref id="pone.0233600.ref031"><label>31</label><mixed-citation publication-type="book"><name><surname>Nyqvist</surname><given-names>M</given-names></name>, <name><surname>Corno</surname><given-names>L</given-names></name>, <name><surname>de Walque</surname><given-names>D</given-names></name>, <name><surname>Svensson</surname><given-names>J</given-names></name>. <source>Using Lotteries to Incentivize Safer Sexual Behavior: Evidence from a Randomized Controlled Trial on HIV Prevention</source>. <publisher-name>Policy Research Working Paper of Human Development and Public Services Team, Development Research Group, World Bank</publisher-name>
<year>2015</year>(7215).</mixed-citation></ref><ref id="pone.0233600.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Thirumurthy</surname><given-names>H</given-names></name>, <name><surname>Ndyabakira</surname><given-names>A</given-names></name>, <name><surname>Marson</surname><given-names>K</given-names></name>, <name><surname>Emperador</surname><given-names>D</given-names></name>, <name><surname>Kamya</surname><given-names>M</given-names></name>, <name><surname>Havlir</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Financial incentives for achieving and maintaining viral suppression among HIV-positive adults in Uganda: a randomised controlled trial</article-title>. <source>Lancet HIV</source>. <year>2019</year>;<volume>6</volume>(<issue>3</issue>):<fpage>e155</fpage>&#x02013;<lpage>e63</lpage>.<pub-id pub-id-type="pmid">30660594</pub-id></mixed-citation></ref><ref id="pone.0233600.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Kohler</surname><given-names>HP</given-names></name>, <name><surname>Thornton</surname><given-names>R</given-names></name>. <article-title>Conditional Cash Transfers and HIV/AIDS Prevention: Unconditionally Promising?</article-title>
<source>World Bank Econ Rev</source>. <year>2012</year>;<volume>26</volume>(<issue>2</issue>):<fpage>165</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">24319306</pub-id></mixed-citation></ref><ref id="pone.0233600.ref034"><label>34</label><mixed-citation publication-type="other">Ending AIDS: Progress Towards the 90-90-90 Targets: Global AIDS Update. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2017.</mixed-citation></ref></ref-list></back><sub-article id="pone.0233600.r001" article-type="aggregated-review-documents"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0233600.r001</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>De Socio</surname><given-names>Giuseppe Vittorio</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2020 Giuseppe Vittorio De Socio</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Giuseppe Vittorio De Socio</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article id="rel-obj001" ext-link-type="doi" xlink:href="10.1371/journal.pone.0233600" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">16 Dec 2019</named-content>
</p><p>PONE-D-19-27665</p><p>A pilot randomized trial of incentive strategies to promote HIV retesting</p><p>PLOS ONE</p><p>Dear Dr. Chamie,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>We would appreciate receiving your revised manuscript by 31 January 2020. When you are ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.</p><p>To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols">http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link></p><p>Please include the following items when submitting your revised manuscript:</p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.</p></list-item></list></p><p>Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Giuseppe Vittorio De Socio, MD, PhD</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal Requirements:</p><p>When submitting your revision, we need you to address these additional requirements.</p><p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p><p><ext-link ext-link-type="uri" xlink:href="http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf">http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf">http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link></p><p>2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified whether consent was suitably informed.</p><p>3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.</p><p>4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/supporting-information">http://journals.plos.org/plosone/s/supporting-information</ext-link></p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p><bold>Comments to the Author</bold></p><p>1. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #1: Partly</p><p>Reviewer #2: Partly</p><p>**********</p><p>2. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #1: Yes</p><p>Reviewer #2: Yes</p><p>**********</p><p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.</p><p>Reviewer #1: Yes</p><p>Reviewer #2: Yes</p><p>**********</p><p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #1: Yes</p><p>Reviewer #2: Yes</p><p>**********</p><p>5. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #1: 1) Interesting study to incentivize retesting of negative individuals vs. incentivizing staying HIV negative. Considering the WHO 2015 Consolidated guidelines on HIV testing services and the upcoming update being released in December 2019 recommends that for most people who test HIV negative additional retesting to rule out being in the window period is not necessary (after 3 months). In addition, the WHO guidelines recommends retesting of individuals with ongoing high risk of HIV infection, not all key populations require retesting every 3 months. It would be helpful for the authors to address the above in the introduction and discussion.</p><p>2) The methods of offering incentives is good; however, please address why incentivizing retesting of negative individuals vs. behavior change to remain negative.</p><p>3) Also address why incentivizing retesting of HIV negative individuals in a resource limited setting that is focusing more on targeted HIV testing services (e.g. partner notification services, risk screening tools in outpatient settings) with linkages to treatment and/or prevention services.</p><p>4) Please address how incentivizing retesting of the study participants is better than current practice in clinics or other HIV testing locations that offer HIV testing services? Please include references that show that there is a need to incentivize retesting of individuals who are HIV negative. There is a lot of peer reviewed literature that shows most HIV negative individuals (with or without ongoing risk) do come back for retesting.</p><p>Reviewer #2: General Comments:</p><p>Background: The study authors outline how the use of financial incentives in the role of HIV re-testing have yet to be studied. While this might be the case, I think the authors could make a stronger case for why the use of financial incentives for retesting would expect to be any different than the use of financial incentives for HIV testing in general? For example, do the authors expect a different outcome than what research has shown with financial incentives for HIV testing? Please clarify.</p><p>Background: This manuscript would benefit from some additional references, particularly in the Background section to provide a stronger case for how the use of financial incentives for HIV retesting would be beneficial for the field. For example, what is the prevalence and/or incidence of HIV infection in Uganda? How often do people get retested in Uganda? If the study authors provided some brief background information about HIV and HIV retesting uptake in Uganda this might also increase clarity for the international reader as to why innovative interventions are needed in this country/region.</p><p>Discussion: Please provide some detail as to how the study findings are comparable to other studies that use financial incentives in low-and-middle income countries in the HIV field.</p><p>Discussion: Please provide a brief statement how the findings from this study could inform future research in the field, and also, remaining knowledge gaps and areas for future research.</p><p>Specific Comments:</p><p>Abstract: In the Results section, the authors have listed number/percentage to display one set of findings but then only percentages for the remaining findings. Please use number/percentage to be consistent.</p><p>Introduction: &#x0201c;Economic incentives have been shown to promote a number of behaviours&#x02026;&#x0201d; This paragraph is not entirely clear. For example, is &#x02018;counseling alone&#x02019; the standard of care? Please rephrase this sentence: &#x0201c;the costs of a given behavior are immediate but the gains may not be realized until later&#x02026;&#x0201d; (could the authors please provide an example?). Also, with this sentence: &#x0201c;insights from behavioural economic theory suggest that individuals display loss aversion&#x02026;&#x0201d; Perhaps the authors provide an example to increase clarity of &#x0201c;loss aversion&#x0201d;?</p><p>Introduction: &#x0201c;A standard approach to implementing&#x02026;&#x0201d; Please provide some references here to increase clarity.</p><p>Introduction: &#x0201c;Individuals may also be aware of a tendency towards present-biased&#x02026;&#x0201d; Please modify this sentence to increase clarity.</p><p>Introduction: What is &#x0201c;Leverage loss aversion&#x0201d;? Please clarify.</p><p>Methods: How long did the authors give the participants to be re-tested? Did participants have to come back at exactly 3 months post study enrollment for re-testing? Please add some study details to increase clarity.</p><p>Methods: &#x0201c;considered at increased risk of HIV, due to drinking, sex work&#x0201d; What does &#x0201c;due to drinking&#x0201d; mean in this case? Please remove or modify to increase clarity.</p><p>Methods: What was the questionnaire that participants were asked to complete? Did the questionnaire only enquire about participant demographics or also measure &#x02018;feasibility&#x02019; and &#x02018;acceptability&#x02019;? How many questions were in the questionnaire? Who developed the questionnaire? Who administered the questionnaire? Was it self-administered?</p><p>Methods: Please specifically define &#x02018;feasibility&#x02019; and &#x02018;acceptability&#x02019; and provide a reference, if possible. Also, please define how these outcomes are measured. In the Discussion section, it states, &#x0201c;were feasible and had high acceptability&#x0201d;, however, it is not clear how these outcomes were measured (and what could be defined as &#x02018;high acceptability&#x02019;).</p><p>Methods: Please define &#x0201c;standard, gain framed cash incentive&#x0201d; to increase clarity. Similarly, what is a &#x0201c;gain framed&#x0201d; incentive?</p><p>Methods: Where did participants need to go to receive retesting? At one clinic site? At several clinic sites?</p><p>Methods: What is standard of care in this case? i.e. &#x0201c;no incentive (control)&#x0201d;</p><p>Methods: &#x0201c;we determined sample size&#x02026;in feasibility of commitment contracts in approximately 70 adults rather than using power calculations&#x02026;&#x0201d; Please consider modifying this section to increase clarity. It is not clear how the study authors determined a sample size of 70 to measure feasibility. Further, was the sample size determined to only measure feasibility or also acceptability? At this point, the study authors could state the minimum number of participants needed in each condition to be powered to detect statistical significant differences between conditions. The study authors could also emphasise in the Results section that the study was not powered to detect statistical significance between conditions, and in the Discussion section, mention that this is an area for future research (would be powered in future trial).</p><p>Methods: Could the study authors please provide greater details as to the venues in which the participants were recruited from? Is there any indication of how many venues the participants were recruited from? Some detail is mentioned in the Results section but it is not very clear, e.g. a clinic waiting room (primary care clinic waiting room?), bars (what kind of bars? How many?). For example, how many transport hubs? How many trading centers? Additionally, what are the &#x0201c;other sites&#x0201d;?</p><p>Results: What is the &#x0201c;Figure: Pilot trial CONSORT diagram&#x0201d;? (p.9)</p><p>Results: It would be helpful if Table 1 was reformatted as it is currently challenging to read when the findings take the space of two rows.</p><p>Discussion: &#x0201c;individuals&#x02019; ability to make deposits may be limited by poverty and other circumstances.&#x0201d; Please provide an example of &#x0201c;other circumstances&#x0201d;. Also, are there any ethical issues to administering commitment contracts in low-and-middle income countries?</p><p>Discussion: &#x0201c;This approach also addressed a limitation observed in commitment contract programs in high-and middle-income countries&#x02026;&#x0201d; Please expand on how this approach addressed this limitation?</p><p>Discussion: &#x0201c;was not powered to detect differences in retesting uptake&#x02026;&#x0201d; Differences by study condition? Differences by participant characteristics? Please elaborate.</p><p>Discussion: &#x0201c;In future studies with more than one retesting opportunity, we suspect retesting might decline over time when incentives are not offered.&#x0201d; Please provide a reference here. Is this based on prior research?</p><p>Discussion: &#x0201c;Our pilot trial was designed to test acceptability and feasibility&#x02026;&#x0201d; Is this paragraph a study limitations paragraph? If yes, please state more directly. For example, &#x0201c;These observations, along with the high prevalence of HIV among adults screened (15%...)&#x02026;&#x0201d; It is not clear if this was stated as a study limitation or strength. Please clarify. Also, the study authors could mention if there were any study biases and how the study authors tried to respond or account for these.</p><p>Conclusion: &#x0201c;As reported rates of &#x0201c;ever&#x0201d; having tested&#x02026;&#x0201d; As the sentence is currently structured, it seems like the study authors are stating that retesting is of &#x0201c;greater priority&#x0201d; than first-time testing. Is this what the study authors meant? Or that &#x0201c;retesting&#x0201d; is also of importance? Please clarify.</p><p>**********</p><p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy">Privacy Policy</ext-link>.</p><p>Reviewer #1: No</p><p>Reviewer #2: No</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" xlink:href="https://pacev2.apexcovantage.com/">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p></body></sub-article><sub-article id="pone.0233600.r002" article-type="author-comment"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0233600.r002</article-id><title-group><article-title>Author response to Decision Letter 0</article-title></title-group><related-article id="rel-obj002" ext-link-type="doi" xlink:href="10.1371/journal.pone.0233600" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">30 Jan 2020</named-content>
</p><p>Response to Reviewers &#x00026; Editor</p><p>Title: A pilot randomized trial of incentive strategies to promote HIV retesting</p><p>Manuscript: PONE-D-19-27665</p><p>Comments from the Editor:</p><p>When submitting your revision, we need you to address these additional requirements.</p><p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p><p><ext-link ext-link-type="uri" xlink:href="http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf">http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf">http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link></p><p>Response: We have ensured that our manuscript meets PLOS ONE&#x02019;s style requirements, including those for file naming.</p><p>2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified whether consent was suitably informed.</p><p>Response: We now provide additional detail regarding participant consent in the Methods (see lines 169-170). All participants provided written informed consent in their preferred language (English or Runyankole, the local language in the region).</p><p>3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.</p><p>Response: Noted &#x02013; thank you. We will provide the study dataset (Supporting Information 1: S1, noted on line 307) should our manuscript be accepted for publication.</p><p>4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information:<ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/supporting-information">http://journals.plos.org/plosone/s/supporting-information</ext-link></p><p>Response: We now provide captions for our Supporting Information files at the end of our manuscript (see lines 306-309).</p><p>&#x02003;</p><p>Response to Reviewers&#x02019; Comments</p><p>Reviewer #1</p><p>1) Interesting study to incentivize retesting of negative individuals vs. incentivizing staying HIV negative. Considering the WHO 2015 Consolidated guidelines on HIV testing services and the upcoming update being released in December 2019 recommends that for most people who test HIV negative additional retesting to rule out being in the window period is not necessary (after 3 months). In addition, the WHO guidelines recommends retesting of individuals with ongoing high risk of HIV infection, not all key populations require retesting every 3 months. It would be helpful for the authors to address the above in the introduction and discussion.</p><p>Response: We now address, in both the Introduction and Discussion, retesting at 3-month intervals and annually (see Introduction, lines 61-66, and Discussion lines 284-292). We reference the WHO Consolidated HIV Testing Guidelines, and now include reference to the November 2019 update as well, which &#x02013; though the update recommends annual retesting for all sexually active individuals in high HIV burden settings (such as Southwestern Uganda, where our pilot took place) &#x02013; also notes that frequent retesting for HIV (i.e. every 3-6 months), &#x0201c;may be warranted based on individual risks and as part of broader HIV prevention interventions.&#x0201d; Uganda Ministry of Health guidelines at the time of this pilot (and currently) recommended retesting for HIV every 3 months in key populations &#x02013; distinct from WHO guidelines, which we now address in the Introduction (see lines 61-66). In this pilot study, we worked with local health officials and community representatives in a generalized epidemic setting (Southwestern Uganda) to identify specific venues frequented by adults that the health officials/community leaders considered to be high-risk for HIV in their community. The HIV positivity of adults tested during recruitment (15%) is more than double that of the population HIV prevalence in the region (7%), suggesting that the input of local health officials/community leaders was accurately identifying high-risk venues. </p><p>2) The methods of offering incentives is good; however, please address why incentivizing retesting of negative individuals vs. behavior change to remain negative.</p><p>Response: The reviewer correctly notes that various behaviors can be incentivized to prevent HIV, including a variety of prevention behaviors such as voluntary medical male circumcision, condom use, HIV retesting or other behaviors. However, many behaviors (condom use, changes in sexual behavior) cannot ethically or practically be observed or verified for the use of conditional financial incentives or deposit contracts. We therefore focused our efforts on a behavior we could verify (HIV retesting) and that can also act as a platform for ongoing counseling and linkage to other emerging combination prevention services over time.</p><p>3) Also address why incentivizing retesting of HIV negative individuals in a resource limited setting that is focusing more on targeted HIV testing services (e.g. partner notification services, risk screening tools in outpatient settings) with linkages to treatment and/or prevention services.</p><p>Response: Retesting of high-risk HIV negative individuals is a form of targeted HIV testing services, as reflected in Ugandan Ministry of Health guidelines for every 3-6 month retesting for key populations, such as the adults we recruited into our study. At the time of our pilot, pre-exposure prophylaxis (PrEP) was not available in government clinics; however, as PrEP becomes increasingly available, retesting at regular intervals (typically every 3 months in PrEP programs) will have even greater relevance among adults accessing PrEP services.</p><p>4) Please address how incentivizing retesting of the study participants is better than current practice in clinics or other HIV testing locations that offer HIV testing services? Please include references that show that there is a need to incentivize retesting of individuals who are HIV negative. There is a lot of peer reviewed literature that shows most HIV negative individuals (with or without ongoing risk) do come back for retesting.</p><p>Response: The primary objective of our pilot trial was not to directly compare the effectiveness of incentivizing HIV retesting vs. counseling participants to retest (current practice), and as such we cannot directly address how incentivizing retesting is better than current practice with our study data. However, regarding the need for interventions to promote retesting (the crux of the Reviewer&#x02019;s insightful comment), peer-reviewed literature on retesting is fairly limited &#x02013; but the several studies published on this topic have documented low rates of retesting at a frequency of at least annually (if not more frequently, such as every 3-6 months, as recommended for high-risk individuals: see response to first Reviewer #1 comment). For example, in a 2011 study that examined mobile testing outreach in South Africa, although 71% of adults tested reported any prior HIV test, only 37% reported testing within the prior 12 months (reference: Kranzer et al, High Prevalence of Self-Reported Undiagnosed HIV despite High Coverage of HIV Testing: A Cross-Sectional Population Based Sero-Survey in South Africa. PLoS One, 2011). Similarly, in a 2013 study from Tanzania evaluating individuals retesting for HIV over three time periods from 2003-10, only 11% of adults participated in retesting (reference: Cawley, C. et al. Low rates of repeat HIV testing despite increased availability of antiretroviral therapy in rural Tanzania: findings from 2003&#x02013;2010. PloS ONE 8, e62212, 2013), and in a 2013 study, Regan et al found only 26% of adults reporting retesting in two South African hospitals (reference: Regan et al, Factors Associated with Self-Reported Repeat HIV Testing after a Negative Result in Durban, South Africa, PLoS One, 2013). Based on our prior work in Southwestern Uganda that sought to recruit all adult men across a community for HIV testing, though any prior HIV testing was common (78% of men), less than half reported testing within the past year (Chamie, et al, AIDS, 2018). These published data highlight low rates of HIV retesting, falling well below WHO recommendations of annual retesting for all adults, let alone more frequent testing of high-risk adults. Lastly, in a recent systematic review of interventions to promote retesting, the authors noted that, &#x0201c;evidence-based interventions that promote frequent and repeat testing more than once a year among individuals at high risk for HIV remain sparse,&#x0201d; (reference: Paschen-Wolff, et al, A Systematic Review of Interventions that Promote Frequent HIV Testing, AIDS and Behavior, 2019), emphasizing the need to better study interventions to promote retesting.</p><p>We now review this literature in greater detail in the revised Introduction section (see lines 67-79, and 80-92).</p><p>&#x02003;</p><p>Reviewer #2: </p><p>General Comments:</p><p>Background: The study authors outline how the use of financial incentives in the role of HIV re-testing have yet to be studied. While this might be the case, I think the authors could make a stronger case for why the use of financial incentives for retesting would expect to be any different than the use of financial incentives for HIV testing in general? For example, do the authors expect a different outcome than what research has shown with financial incentives for HIV testing? Please clarify.</p><p>Response: We have now clarified in greater detail why retesting for HIV after a negative test is likely to be a distinct behavior from incentivizing HIV testing in general (see Introduction, lines 80-92). Motivation to retest for HIV after a negative test may be lower than testing for HIV in general, given studies that have shown perceptions that retesting is unnecessary (e.g. Orne-Gliemann, J., et al. (2016). "Community perceptions of repeat HIV-testing: experiences of the ANRS 12249 Treatment as Prevention trial in rural South Africa." AIDS care 28 Suppl 3: 14-23).</p><p>Background: This manuscript would benefit from some additional references, particularly in the Background section to provide a stronger case for how the use of financial incentives for HIV retesting would be beneficial for the field. For example, what is the prevalence and/or incidence of HIV infection in Uganda? How often do people get retested in Uganda? If the study authors provided some brief background information about HIV and HIV retesting uptake in Uganda this might also increase clarity for the international reader as to why innovative interventions are needed in this country/region.</p><p>Response: We now provide additional references and information in our Introduction section to offer more background information about the need for interventions to promote retesting for HIV, and about HIV and retesting uptake among high-risk adults available from published studies in sub-Saharan Africa, including Uganda. (See Introduction, lines 67-79, and 80-92). </p><p>Discussion: Please provide some detail as to how the study findings are comparable to other studies that use financial incentives in low-and-middle income countries in the HIV field.</p><p>Response: We now include greater detail on how our study findings are comparable to other studies that have used incentives for HIV testing in low- and middle-income settings, including reference to a systematic review of incentives for HIV testing (see Discussion, lines 251-270).</p><p>Discussion: Please provide a brief statement how the findings from this study could inform future research in the field, and also, remaining knowledge gaps and areas for future research.</p><p>Response: We now provide a brief statement about how the findings from this study could inform future research in the field and have provide knowledge gaps remain as a basis for areas of future research (see Discussion, lines 265-270).</p><p>Specific Comments:</p><p>Abstract: In the Results section, the authors have listed number/percentage to display one set of findings but then only percentages for the remaining findings. Please use number/percentage to be consistent.</p><p>Response: We now provide number/percentages throughout the Results section of the Abstract for consistency.</p><p>Introduction: &#x0201c;Economic incentives have been shown to promote a number of behaviours&#x02026;&#x0201d; This paragraph is not entirely clear. For example, is &#x02018;counseling alone&#x02019; the standard of care? </p><p>Response: We have revised this paragraph (see Introduction, lines 80-92) for greater clarity, including the standard of care, which is counseling alone in this setting.</p><p>Please rephrase this sentence: &#x0201c;the costs of a given behavior are immediate but the gains may not be realized until later&#x02026;&#x0201d; (could the authors please provide an example?). Also, with this sentence: &#x0201c;insights from behavioural economic theory suggest that individuals display loss aversion&#x02026;&#x0201d; Perhaps the authors provide an example to increase clarity of &#x0201c;loss aversion&#x0201d;?</p><p>Response: We have rephrased these sentences highlighted by the reviewer, providing examples for the phrase discussing &#x0201c;costs of a given behavior&#x0201d;, as well as an example to clarify loss aversion (see Introduction, lines 80-84, and lines 93-99).</p><p>Introduction: &#x0201c;A standard approach to implementing&#x02026;&#x0201d; Please provide some references here to increase clarity.</p><p>Response: We now provide references for this section (Introduction, lines 93-95).</p><p>Introduction: &#x0201c;Individuals may also be aware of a tendency towards present-biased&#x02026;&#x0201d; Please modify this sentence to increase clarity.</p><p>Response: We have revised this sentence in an effort to increase clarity (lines 99-110).</p><p>Introduction: What is &#x0201c;Leverage loss aversion&#x0201d;? Please clarify.</p><p>Response: We have revised this sentence in an effort to increase clarity (lines 95-99).</p><p>Methods: How long did the authors give the participants to be re-tested? Did participants have to come back at exactly 3 months post study enrollment for re-testing? Please add some study details to increase clarity.</p><p>Response: As we note in the Methods (please see Methods, lines 155-157) participants did not have to return for retesting at exactly 3 months post-enrollment but were instead provided an interval of 2-3 months to return to the clinic for retesting.</p><p>Methods: &#x0201c;considered at increased risk of HIV, due to drinking, sex work&#x0201d; What does &#x0201c;due to drinking&#x0201d; mean in this case? Please remove or modify to increase clarity.</p><p>Response: We now have modified this phrase for further clarity (see Methods, lines 126-128). The phrase now states, &#x0201c;due to drinking at bars associated with transactional sex.&#x0201d;</p><p>Methods: What was the questionnaire that participants were asked to complete? Did the questionnaire only enquire about participant demographics or also measure &#x02018;feasibility&#x02019; and &#x02018;acceptability&#x02019;? How many questions were in the questionnaire? Who developed the questionnaire? Who administered the questionnaire? Was it self-administered?</p><p>Response: The questionnaire was developed by the investigators, administered by study staff, and sought to gather information on both demographics, socioeconomic status, HIV risk behavior, prior HIV testing behavior and testing preferences. There were 62 questions in the questionnaire. These details are now provided in the Methods, (see lines 143-145). </p><p>Methods: Please specifically define &#x02018;feasibility&#x02019; and &#x02018;acceptability&#x02019; and provide a reference, if possible. Also, please define how these outcomes are measured. In the Discussion section, it states, &#x0201c;were feasible and had high acceptability&#x0201d;, however, it is not clear how these outcomes were measured (and what could be defined as &#x02018;high acceptability&#x02019;).</p><p>Response: We now define acceptability in our methods (see lines 160-162. We pre-specified our definition of acceptability and feasibility in our study protocol (included with our PLoS One submission). Feasibility and how we measured these outcomes are clearly defined in our Methods as well (see lines 162-163). As this was a pilot trial, we did not pre-specify the definition of &#x0201c;high&#x0201d; acceptability, but we now clarify in our Discussion (line 221) that when we indicate &#x0201c;high acceptability&#x0201d;, this refers to the finding that 95% of eligible participants agreed to proceed with enrollment and continued with trial participation after randomization.</p><p>Methods: Please define &#x0201c;standard, gain framed cash incentive&#x0201d; to increase clarity. Similarly, what is a &#x0201c;gain framed&#x0201d; incentive?</p><p>Response: A &#x0201c;gain-framed&#x0201d; incentive is a simple financial reward (or bonus) provided for doing a given, desired behavior. We now clarify this phrase (see line 150).</p><p>Methods: Where did participants need to go to receive retesting? At one clinic site? At several clinic sites?</p><p>Response: Participants needed to return to the same, single clinic site to receive retesting. We now clarify this point in the Methods (see lines 159-160).</p><p>Methods: What is standard of care in this case? i.e. &#x0201c;no incentive (control)&#x0201d;</p><p>Response: The standard of care is counseling to promote retesting without the use of an incentive (i.e. what we provided in our control arm: no incentive, but counseling) &#x02013; and this standard is now clarified in our Introduction (see lines 90-91).</p><p>Methods: &#x0201c;we determined sample size&#x02026;in feasibility of commitment contracts in approximately 70 adults rather than using power calculations&#x02026;&#x0201d; Please consider modifying this section to increase clarity. It is not clear how the study authors determined a sample size of 70 to measure feasibility. Further, was the sample size determined to only measure feasibility or also acceptability? At this point, the study authors could state the minimum number of participants needed in each condition to be powered to detect statistical significant differences between conditions. The study authors could also emphasise in the Results section that the study was not powered to detect statistical significance between conditions, and in the Discussion section, mention that this is an area for future research (would be powered in future trial).</p><p>Response: We did not use power calculations to determine a sample size, and we feel that presenting the sample sizes needed to detect statistical differences between arms (which is a total sample size of 525 participants in our subsequent 3-arm trial to promote retesting) would introduce more confusion than clarity. We now emphasize in our Results section that the study was not powered to detect statistically significant differences in retesting between arms (see lines 214-215) and mention that this is an area for future research in the Discussion section (see lines 224-225).</p><p>Methods: Could the study authors please provide greater details as to the venues in which the participants were recruited from? Is there any indication of how many venues the participants were recruited from? Some detail is mentioned in the Results section but it is not very clear, e.g. a clinic waiting room (primary care clinic waiting room?), bars (what kind of bars? How many?). For example, how many transport hubs? How many trading centers? Additionally, what are the &#x0201c;other sites&#x0201d;?</p><p>Response: We now include greater detail on the venues from which participants were recruited in the Methods section (see page 7, lines 127-132). We also now include greater detail on the venues in our Results section, including clarification as to what the &#x0201c;other sites&#x0201d; were and the number of venues (see page 10, lines 179-182).</p><p>Results: What is the &#x0201c;Figure: Pilot trial CONSORT diagram&#x0201d;? (p.9)</p><p>Response: This Figure was submitted with the manuscript, and is a CONSORT diagram, now referenced, that is recommended to use to provide detail on recruitment, enrollment and retention of participants in pilot trials. We have elaborated on this in the description of the Figure (see lines 201-202).</p><p>Results: It would be helpful if Table 1 was reformatted as it is currently challenging to read when the findings take the space of two rows.</p><p>Response: The formatting is based on PLoS One requirements to have double spacing of tables and is not how the table will appear if accepted for publication by PLoS One. Ultimately, if the manuscript is accepted, we will request that the table have findings on a single row.</p><p>Discussion: &#x0201c;individuals&#x02019; ability to make deposits may be limited by poverty and other circumstances.&#x0201d; Please provide an example of &#x0201c;other circumstances&#x0201d;. Also, are there any ethical issues to administering commitment contracts in low-and-middle income countries?</p><p>Response: We have removed the phrase, &#x0201c;other circumstances,&#x0201d; as we feel poverty is the primary driver of one&#x02019;s ability to make a deposit (see line 232). As commitment contracts are voluntary, and suggested deposits are considered low, we do not believe there are any ethical issues to administering commitment contracts.</p><p>Discussion: &#x0201c;This approach also addressed a limitation observed in commitment contract programs in high-and middle-income countries&#x02026;&#x0201d; Please expand on how this approach addressed this limitation?</p><p>Response: We now expand on how this approach addressed this limitation (see Discussion, lines 236-238).</p><p>Discussion: &#x0201c;was not powered to detect differences in retesting uptake&#x02026;&#x0201d; Differences by study condition? Differences by participant characteristics? Please elaborate.</p><p>Response: We now clarify this phrase, as it was used to indicate detection of differences by study condition (see lines 273).</p><p>Discussion: &#x0201c;In future studies with more than one retesting opportunity, we suspect retesting might decline over time when incentives are not offered.&#x0201d; Please provide a reference here. Is this based on prior research?</p><p>Response: This suspicion that retesting might decline over time is based on the observation that with healthy behaviors that require repeated/continued engagement (such as smoking cessation or exercise), the withdrawal of incentives can lead to a decline in healthy behavior from the levels of behavior achieved with an incentive. We also now include an example and a reference for this tendency observed in prior research in the manuscript (see line 279).</p><p>Discussion: &#x0201c;Our pilot trial was designed to test acceptability and feasibility&#x02026;&#x0201d; Is this paragraph a study limitations paragraph? If yes, please state more directly. For example, &#x0201c;These observations, along with the high prevalence of HIV among adults screened (15%...)&#x02026;&#x0201d; It is not clear if this was stated as a study limitation or strength. Please clarify. Also, the study authors could mention if there were any study biases and how the study authors tried to respond or account for these.</p><p>Response: We now directly state that this paragraph is a study limitations paragraph, and enumerate our limitations (&#x0201c;First&#x0201d;, &#x0201c;Second&#x0201d;, &#x0201c;Third&#x0201d;, etc.), to distinguish them from the strengths we highlight in response to these limitations (see lines 271-296).</p><p>Conclusion: &#x0201c;As reported rates of &#x0201c;ever&#x0201d; having tested&#x02026;&#x0201d; As the sentence is currently structured, it seems like the study authors are stating that retesting is of &#x0201c;greater priority&#x0201d; than first-time testing. Is this what the study authors meant? Or that &#x0201c;retesting&#x0201d; is also of importance? Please clarify.</p><p>Response: We are not stating that retesting is of greater priority than first-time testing in general, but rather making the point that as rates of &#x0201c;ever testing&#x0201d; reach very high levels, the relative importance of retesting increases. We now clarify this point (see lines 299-300).</p><supplementary-material content-type="local-data" id="pone.0233600.s004"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers Retest Pilot v31Jan2020.docx</named-content></p></caption><media xlink:href="pone.0233600.s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></body></sub-article><sub-article id="pone.0233600.r003" article-type="aggregated-review-documents"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0233600.r003</article-id><title-group><article-title>Decision Letter 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>De Socio</surname><given-names>Giuseppe Vittorio</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2020 Giuseppe Vittorio De Socio</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Giuseppe Vittorio De Socio</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article id="rel-obj003" ext-link-type="doi" xlink:href="10.1371/journal.pone.0233600" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">19 Feb 2020</named-content>
</p><p>PONE-D-19-27665R1</p><p>A pilot randomized trial of incentive strategies to promote HIV retesting</p><p>PLOS ONE</p><p>Dear Dr. Chamie,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>We really appreciate the efforts made by the authors, but as you will see, the Reviewer 2 still has concerns that require response.</p><p>We would appreciate receiving your revised manuscript by March 30. When you are ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.</p><p>To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols">http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link></p><p>Please include the following items when submitting your revised manuscript:</p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.</p></list-item></list></p><p>Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Giuseppe Vittorio De Socio, MD, PhD</p><p>Academic Editor</p><p>PLOS ONE</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p><bold>Comments to the Author</bold></p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#x0201c;Comments to the Author&#x0201d; section, enter your conflict of interest statement in the &#x0201c;Confidential to Editor&#x0201d; section, and submit your "Accept" recommendation.</p><p>Reviewer #1: All comments have been addressed</p><p>Reviewer #2: All comments have been addressed</p><p>**********</p><p>2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #1: Partly</p><p>Reviewer #2: Partly</p><p>**********</p><p>3. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #1: Yes</p><p>Reviewer #2: Yes</p><p>**********</p><p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.</p><p>Reviewer #1: Yes</p><p>Reviewer #2: Yes</p><p>**********</p><p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #1: Yes</p><p>Reviewer #2: Yes</p><p>**********</p><p>6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #1: It is technically sound and all comments were addressed. However, incentivizing retesting of negative individuals vs. prevention to remain negative in resource limited settings is not sustainable and somewhat conflicts the updated 2019 consolidated guidelines recommendations on targeted testing in changing epidemics.</p><p>Reviewer #2: The study authors have made some substantial changes to this manuscript, which has helped to increase clarity. I have provided a few more suggested modifications for your consideration:</p><p>Title: The title is a bit too concise. Please consider adding the country/location of the study and/or the study population group. For example, &#x0201c;to promote HIV restesting among &#x02026;. In Uganda&#x0201d;</p><p>Abstract: &#x0201c;Retesting for HIV is critical to identifying newly-infected persons and reinforcing prevention&#x02026;&#x0201d; The &#x02018;reinforcing&#x02019; term is unclear. Do the authors mean reinforcing prevention efforts? Prevention messaging? Please modify.</p><p>Abstract: &#x0201c;Incentives can increase one-time testing&#x02026;&#x0201d; Based on? Perhaps better to put &#x02018;may increase&#x02019;?</p><p>Entire Manuscript: As much as possible, it is better to use &#x02018;HIV retesting&#x02019; instead of &#x02018;retesting&#x02019; as a firm reminder to the reader that the authors are referring to retesting of HIV. For example, Pg. 9 &#x0201c;the deposits would be lost if they did not return for HIV retesting &#x02026;&#x0201d;. Also, Pg.14, &#x0201c;clear understanding of the benefits of HIV retesting &#x02026;&#x0201d;</p><p>Abstract: &#x0201c;to promote retesting three months later&#x02026;&#x0201d; Do the authors mean, three months post-study enrolment? Please clarify.</p><p>Abstract: &#x0201c;Contracts sought to promote retesting by leveraging &#x02026;&#x0201d; The study authors explain this sentence in the manuscript, so fine to leave there, but it is a bit confusing in the Abstract. Could remove.</p><p>Abstract: &#x0201c;(proportion making deposits)&#x0201d; &#x02013; Perhaps, &#x02018;proportion of participants making deposits&#x02019;?</p><p>Abstract: &#x0201c;Overall, 93 (76%) participants retested&#x0201d; &#x02013; Please consider adding &#x0201c;were retested for HIV&#x0201d; &#x02013; Again, making clear to the reader that we are speaking to retesting of HIV.</p><p>Introduction: The first section of the Introduction is verbose and hard to understand. Please modify. For example, what are combination prevention approaches?</p><p>Introduction: &#x0201c;Retesting of high-risk, HIV-uninfected persons is critical to&#x02026;&#x0201d; Please add a reference after this point.</p><p>Introduction: &#x0201c;Retesting also offer an opportunity to &#x02026;&#x0201d; Please add a reference after this point.</p><p>Introduction: &#x0201c;may be perceived as low, particularly if access&#x0201d; Access to what? A clinic? Please clarify.</p><p>Introduction: &#x0201c;incentives can be made more powerful&#x0201d;. I am not sure that &#x02018;powerful&#x02019; is the right word here. Do the authors mean &#x02018;effective&#x02019; or &#x02018;impactful&#x02019;?</p><p>Introduction: &#x0201c;Recent studies have indicated that &#x02026;&#x0201d; Please add the references to the &#x02018;recent studies&#x02019; here.</p><p>Introduction: &#x0201c;Very few incentive-based approaches&#x02026;&#x0201d; Please add references here to support this statement.</p><p>Introduction: &#x0201c;We assessed the feasibility and acceptability &#x02026;&#x0201d; This statement could be made stronger by stating, &#x0201c;The aim of this study is to&#x02026;&#x0201d;</p><p>Methods: &#x0201c;due to drinking at bars associated with transactional sex&#x02026;&#x0201d; This sentence is unclear. Do the authors mean that the &#x0201c;adults considered at increased risk of HIV due to attendance at &#x02026; and behaviours in sex work &#x02026;?&#x0201d; Please modify.</p><p>Methods: &#x0201c;rapid HIV antibody testing&#x0201d;. Could the study authors please list the type of test that was used (e.g. brand name, etc.).</p><p>Results: &#x0201c;HIV positivity varied by recruitment site &#x02026;&#x0201d; Was this variance expected? If no, please list this more directly in the Limitations section. For example, following the sentence, &#x0201c;Possibly suggesting that we did not reach a high-risk population group through our selection of recruitment study sites &#x02026;&#x0201d;</p><p>Results: Please list as &#x02018;Figure 1&#x02019; and &#x02018;Table 1&#x02019;.</p><p>Results: Figure 1 is quite helpful and should be included as part of the manuscript instead of supplementary material, if possible (i.e. it was not embedded in the manuscript like the Table).</p><p>Discussion: &#x0201c;the optimal balance between deposit amounts that are acceptable versus of sufficient value to generate &#x02026;&#x0201d; I know what the authors are trying to say, but I think it is the &#x02018;versus&#x02019; that makes the statement a bit awkward. Could change to &#x02018;that are acceptable and of sufficient value&#x02019;.</p><p>Discussion: &#x0201c;other HIV-related behaviours and outcomes, such as voluntary medical male &#x02026;&#x0201d; If the study authors keep the examples of VMMC and HIV viral suppression in this specific sentence, then references should be used. The authors could also remove these specific examples in this sentence, given that the examples are provided in the following sentence with references. It keeps the overall paragraph less repetitive. For example, &#x0201c;other HIV-related behaviours and outcomes. The effectiveness of these strategies when studied &#x02026;Examples of effective strategies have included &#x02026;&#x0201d;</p><p>Discussion: &#x0201c;decreasing engagement in risky sex among men&#x02026;&#x0201d; This sentence is a bit unclear. Is this referring to men who have sex with men? Or more that men are engaging in high-risk sexual activities? Please clarify.</p><p>Discussion: &#x0201c;whether commitment contract participants&#x02026;&#x0201d; This is a bit of lengthy adjective. Perhaps change to &#x0201c;whether participants who agree to commitment contracts&#x02026;&#x0201d;</p><p>Discussion: &#x0201c;Fourth, no seroconversions were observed&#x02026;&#x0201d; Again, re-emphasise HIV. &#x0201c;Fourth, there were no HIV seroconversions observed in this study &#x02026;&#x0201d;</p><p>Discussion: &#x0201c;However, participants reported high-risk sexual behaviour&#x02026;&#x0201d; The sexual behaviours of the participants were presented briefly in Table 1. Are there other components of the questionnaire that can be mentioned in paragraph 1 or 2 of the Results section or placed in Table 1? (but not to be mentioned in both places). The authors used a 62-item questionnaire, so there could be more Results presented from the questionnaire in either Table 1 or written in the Results section. The authors could also provide a copy of the 62-item questionnaire in the Supplementary information section.</p><p>It might be clearer if the study authors use &#x02018;Table 1&#x02019; to highlight baseline characteristics of study participants (study demographics, sexual activity behaviours, etc.) and &#x02018;Table 2&#x02019; to show study outcomes (e.g. &#x02018;HIV retesting 2-3 months following randomisation&#x02019; &#x02018;Deposit made to commitment contract&#x02019;) because the title of Table 1 currently is baseline characteristics, and HIV retesting, for example, is not a baseline characteristic. There are also empty spaces in some parts of Table 1 and then &#x02018;N/A&#x02019; in other sections, would be more helpful to be consistent.</p><p>**********</p><p>7. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy">Privacy Policy</ext-link>.</p><p>Reviewer #1: No</p><p>Reviewer #2: No</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" xlink:href="https://pacev2.apexcovantage.com/">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p></body></sub-article><sub-article id="pone.0233600.r004" article-type="author-comment"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0233600.r004</article-id><title-group><article-title>Author response to Decision Letter 1</article-title></title-group><related-article id="rel-obj004" ext-link-type="doi" xlink:href="10.1371/journal.pone.0233600" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">24 Mar 2020</named-content>
</p><p>Response to Reviewers &#x00026; Editor</p><p>Title: A pilot randomized trial of incentive strategies to promote HIV retesting</p><p>Manuscript: PONE-D-19-27665</p><p>Response to Reviewers&#x02019; Comments</p><p>Reviewer #1</p><p>General Comments:</p><p>It is technically sound and all comments were addressed. However, incentivizing retesting of negative individuals vs. prevention to remain negative in resource limited settings is not sustainable and somewhat conflicts the updated 2019 consolidated guidelines recommendations on targeted testing in changing epidemics.</p><p>Response: We are pleased that Reviewer 1 finds all of the comments addressed and the manuscript technically sound. The use of incentives are endorsed by the WHO 2019 Consolidated guidelines, and could be used to increase retesting that is targeted to very high-risk people who test negative for HIV, but based on risk behavior, merit retesting 3-6 months in the future &#x02013; a recommendation in line with WHO guidelines. Furthermore, deposit contracts are potentially cost saving compared to standard incentives, as they leverage voluntary deposits by adults who wish to participate in them. However, our manuscript is not designed to evaluate or test the sustainability of this approach, but rather to understand the feasibility and acceptability of incentive strategies to promote HIV retesting. We agree that further research is needed to address the question of cost-effectiveness and sustainability.</p><p>Reviewer #2: </p><p>General Comments:</p><p>The study authors have made some substantial changes to this manuscript, which has helped to increase clarity. I have provided a few more suggested modifications for your consideration:</p><p>Specific Comments:</p><p>Title: The title is a bit too concise. Please consider adding the country/location of the study and/or the study population group. For example, &#x0201c;to promote HIV restesting among &#x02026;. In Uganda&#x0201d; </p><p>Response: We have revised the title to include the study location as rural Uganda. </p><p>Abstract: &#x0201c;Retesting for HIV is critical to identifying newly-infected persons and reinforcing prevention&#x02026;&#x0201d; The &#x02018;reinforcing&#x02019; term is unclear. Do the authors mean reinforcing prevention efforts? Prevention messaging? Please modify. Page 4 of 6 </p><p>Response: We have revised this sentence to clarify that HIV retesting can reinforce prevention efforts among at-risk adults. </p><p>Abstract: &#x0201c;Incentives can increase one-time testing&#x02026;&#x0201d; Based on? Perhaps better to put &#x02018;may increase&#x02019;? </p><p>Response: This statement in the abstract is based on multiple studies, including trials and a systematic review, that have demonstrated that incentives can increase one-time HIV testing. We provide these references in our Introduction section (page 6, lines 81-85). </p><p>Entire Manuscript: As much as possible, it is better to use &#x02018;HIV retesting&#x02019; instead of &#x02018;retesting&#x02019; as a firm reminder to the reader that the authors are referring to retesting of HIV. For example, Pg. 9 &#x0201c;the deposits would be lost if they did not return for HIV retesting &#x02026;&#x0201d;. Also, Pg.14, &#x0201c;clear understanding of the benefits of HIV retesting &#x02026;&#x0201d; </p><p>Response: We have revised the manuscript to emphasize that our aim and outcome was increase in HIV retesting. These clarifications include the reviewer&#x02019;s specific suggestions to add &#x0201c;HIV&#x0201d; to the term &#x0201c;retesting&#x0201d; on pages 9 and 14, as well as throughout the manuscript. </p><p>Abstract: &#x0201c;to promote retesting three months later&#x02026;&#x0201d; Do the authors mean, three months post-study enrolment? Please clarify. </p><p>Response: We have revised this sentence to clarify that our outcome was HIV retesting at three months after study enrollment.</p><p>Abstract: &#x0201c;Contracts sought to promote retesting by leveraging &#x02026;&#x0201d; The study authors explain this sentence in the manuscript, so fine to leave there, but it is a bit confusing in the Abstract. Could remove. </p><p>Response: We recognize that this term is not fully defined in the abstract, but it is a well-known behavioral economic term that is well-defined in our manuscript, and key to how our deposit intervention works, so we have chosen to leave it in the manuscript.</p><p>Abstract: &#x0201c;(proportion making deposits)&#x0201d; &#x02013; Perhaps, &#x02018;proportion of participants making deposits&#x02019;? </p><p>Response: We have revised this sentence to clarify that feasibility was assessed as the proportion of participants who chose to make a deposit.</p><p>Abstract: &#x0201c;Overall, 93 (76%) participants retested&#x0201d; &#x02013; Please consider adding &#x0201c;were retested for HIV&#x0201d; &#x02013; Again, making clear to the reader that we are speaking to retesting of HIV. </p><p>Response: We have revised this sentence to clarify that our outcome was HIV retesting uptake. </p><p>Introduction: The first section of the Introduction is verbose and hard to understand. Please modify. For example, what are combination prevention approaches? </p><p>Response: We now provide some examples of combination HIV prevention approaches to provide greater clarity to the first paragraph of the Introduction.</p><p>Introduction: &#x0201c;Retesting of high-risk, HIV-uninfected persons is critical to&#x02026;&#x0201d; Please add a reference after this point. </p><p>Response: We now provide references for this sentence.</p><p>Introduction: &#x0201c;Retesting also offer an opportunity to &#x02026;&#x0201d; Please add a reference after this point. </p><p>Response: We now provide a reference for this point.</p><p>Introduction: &#x0201c;may be perceived as low, particularly if access&#x0201d; Access to what? A clinic? Please clarify. </p><p>Response: This sentence has been revised to specify that access to testing and transportation to clinics may be costly for some individuals. </p><p>Introduction: &#x0201c;incentives can be made more powerful&#x0201d;. I am not sure that &#x02018;powerful&#x02019; is the right word here. Do the authors mean &#x02018;effective&#x02019; or &#x02018;impactful&#x02019;? </p><p>Response: This sentence has been revised to clarify that the use of loss aversion principles can make incentives more effective. </p><p>Introduction: &#x0201c;Recent studies have indicated that &#x02026;&#x0201d; Please add the references to the &#x02018;recent studies&#x02019; here.</p><p>Response: We now provide references for this sentence.</p><p>Introduction: &#x0201c;Very few incentive-based approaches&#x02026;&#x0201d; Please add references here to support this statement. </p><p>Response: This phrase is based on our own extensive review of the literature, and does not have a specific reference, as currently there is no systematic review of incentive-based approaches that leverage loss aversion. We have revised this sentence to clarify that, &#x0201c;to our knowledge, no incentive-based approaches in sub-Saharan Africa have attempted to leverage loss aversion for behavior change through commitment contracts.&#x0201d; </p><p>Introduction: &#x0201c;We assessed the feasibility and acceptability &#x02026;&#x0201d; This statement could be made stronger by stating, &#x0201c;The aim of this study is to&#x02026;&#x0201d; </p><p>Response: This sentence has been revised, based on the reviewer&#x02019;s suggestion to strengthen the message and highlight the study aim. </p><p>Methods: &#x0201c;due to drinking at bars associated with transactional sex&#x02026;&#x0201d; This sentence is unclear. Do the authors mean that the &#x0201c;adults considered at increased risk of HIV due to attendance at &#x02026; and behaviours in sex work &#x02026;?&#x0201d; Please modify. </p><p>Response: This sentence has been revised to clarify that individuals who attended bars and sites of sex work were considered to be at increased risk of HIV-infection and were specifically recruited for this study. </p><p>Methods: &#x0201c;rapid HIV antibody testing&#x0201d;. Could the study authors please list the type of test that was used (e.g. brand name, etc.). </p><p>Response: The study performed HIV antibody testing using the Alere DetermineTM HIV-1/2 Ag/Ab Combo, followed by the Chembio HIV 1/2 STAT-PAK&#x000ae; and SD Bioline HIV-1/2 assays for confirmation of Determine-positive results. This information has been added to the Methods section.</p><p>Results: &#x0201c;HIV positivity varied by recruitment site &#x02026;&#x0201d; Was this variance expected? If no, please list this more directly in the Limitations section. For example, following the sentence, &#x0201c;Possibly suggesting that we did not reach a high-risk population group through our selection of recruitment study sites &#x02026;&#x0201d; </p><p>Response: This variance was expected. </p><p>Results: Please list as &#x02018;Figure 1&#x02019; and &#x02018;Table 1&#x02019;. </p><p>Response: The figure and table labels have been revised to read &#x0201c;Figure 1&#x0201d; and &#x0201c;Table 1&#x0201d; as suggested. </p><p>Results: Figure 1 is quite helpful and should be included as part of the manuscript instead of supplementary material, if possible (i.e. it was not embedded in the manuscript like the Table). </p><p>Response: We are pleased that Reviewer 2 finds Figure 1 helpful. Figure 1 will be included as part of the manuscript (it is not supplementary material). However, PlosOne requires that figures be uploaded as separate files and not be embedded in the manuscript.</p><p>Discussion: &#x0201c;the optimal balance between deposit amounts that are acceptable versus of sufficient value to generate &#x02026;&#x0201d; I know what the authors are trying to say, but I think it is the &#x02018;versus&#x02019; that makes the statement a bit awkward. Could change to &#x02018;that are acceptable and of sufficient value&#x02019;. Page 5 of 6 </p><p>Response: This sentence has been revised to clarify that future studies may need to determine the optimal balance between deposit contract amounts that are acceptable and of sufficient value to generate loss aversion. </p><p>Discussion: &#x0201c;other HIV-related behaviours and outcomes, such as voluntary medical male &#x02026;&#x0201d; If the study authors keep the examples of VMMC and HIV viral suppression in this specific sentence, then references should be used. The authors could also remove these specific examples in this sentence, given that the examples are provided in the following sentence with references. It keeps the overall paragraph less repetitive. For example, &#x0201c;other HIV-related behaviours and outcomes. The effectiveness of these strategies when studied &#x02026;Examples of effective strategies have included &#x02026;&#x0201d; </p><p>Response: Voluntary medical male circumcision and HIV viral suppression have been removed from the sentence indicated in this comment from the reviewer. These specific examples have been retained later in the same paragraph with references cited. </p><p>Discussion: &#x0201c;decreasing engagement in risky sex among men&#x02026;&#x0201d; This sentence is a bit unclear. Is this referring to men who have sex with men? Or more that men are engaging in high-risk sexual activities? Please clarify. </p><p>Response: This sentence has been clarified to indicate that the study in question assessed high-risk sexual activity among men in Malawi. </p><p>Discussion: &#x0201c;whether commitment contract participants&#x02026;&#x0201d; This is a bit of lengthy adjective. Perhaps change to &#x0201c;whether participants who agree to commitment contracts&#x02026;&#x0201d; </p><p>Response: This sentence has been revised as suggested by the reviewer.</p><p>Discussion: &#x0201c;Fourth, no seroconversions were observed&#x02026;&#x0201d; Again, re-emphasise HIV. &#x0201c;Fourth, there were no HIV seroconversions observed in this study &#x02026;&#x0201d; </p><p>Response: This sentence has been revised to emphasize that the outcome being observed was HIV seroconversions.</p><p>Discussion: &#x0201c;However, participants reported high-risk sexual behaviour&#x02026;&#x0201d; The sexual behaviours of the participants were presented briefly in Table 1. Are there other components of the questionnaire that can be mentioned in paragraph 1 or 2 of the Results section or placed in Table 1? (but not to be mentioned in both places). The authors used a 62-item questionnaire, so there could be more Results presented from the questionnaire in either Table 1 or written in the Results section. The authors could also provide a copy of the 62-item questionnaire in the Supplementary information section. </p><p>Response: The questions regarding sexual risk that we asked in our 62-item questionnaire were brief and are all included in Table 1. We now provide a copy of the 62-item questionnaire for inclusion in the Supplementary materials.</p><p>It might be clearer if the study authors use &#x02018;Table 1&#x02019; to highlight baseline characteristics of study participants (study demographics, sexual activity behaviours, etc.) and &#x02018;Table 2&#x02019; to show study outcomes (e.g. &#x02018;HIV retesting 2-3 months following randomisation&#x02019; &#x02018;Deposit made to commitment contract&#x02019;) because the title of Table 1 currently is baseline characteristics, and HIV retesting, for example, is not a baseline characteristic. There are also empty spaces in some parts of Table 1 and then &#x02018;N/A&#x02019; in other sections, would be more helpful to be consistent.</p><p>Response: We have opted to present a single table, as the retesting outcomes are brief (3 rows), and the title of Table 1 is &#x0201c;Baseline characteristics and HIV retesting uptake,&#x0201d; indicating that both outcomes are presented in this single table. We have added &#x0201c;N/A&#x0201d; to the empty spaces and thank the Reviewer for this suggestion.</p><supplementary-material content-type="local-data" id="pone.0233600.s005"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers Retest Pilot v24Mar2020.docx</named-content></p></caption><media xlink:href="pone.0233600.s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></body></sub-article><sub-article id="pone.0233600.r005" article-type="aggregated-review-documents"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0233600.r005</article-id><title-group><article-title>Decision Letter 2</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>De Socio</surname><given-names>Giuseppe Vittorio</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2020 Giuseppe Vittorio De Socio</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Giuseppe Vittorio De Socio</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article id="rel-obj005" ext-link-type="doi" xlink:href="10.1371/journal.pone.0233600" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">21 Apr 2020</named-content>
</p><p>PONE-D-19-27665R2</p><p>A pilot randomized trial of incentive strategies to promote HIV retesting in rural Uganda</p><p>PLOS ONE</p><p>Dear Dr. Chamie,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>We would appreciate receiving your revised manuscript by the next 4 weeks. When you are ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.</p><p>To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols">http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link></p><p>Please include the following items when submitting your revised manuscript:</p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.</p></list-item></list></p><p>Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Giuseppe Vittorio De Socio, MD, PhD</p><p>Academic Editor</p><p>PLOS ONE</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p><bold>Comments to the Author</bold></p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#x0201c;Comments to the Author&#x0201d; section, enter your conflict of interest statement in the &#x0201c;Confidential to Editor&#x0201d; section, and submit your "Accept" recommendation.</p><p>Reviewer #3: (No Response)</p><p>**********</p><p>2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #3: Yes</p><p>**********</p><p>3. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #3: Yes</p><p>**********</p><p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.</p><p>Reviewer #3: Yes</p><p>**********</p><p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #3: Yes</p><p>**********</p><p>6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #3: This is a very interesting study assessing the feasibility and acceptability of various incentive strategies, including commitment contracts that required a baseline deposit, to promote HIV retesting among at-risk adults in rural Uganda.</p><p>Some minor comments considered important.</p><p>Although the methods sections is well detailed, the authors have not explicitly included a statistical analysis section. For example descriptive statistics presented as means(SD), median(IQR) and counts(%ages), also the authors have presented proportions with 95%CI using exact methods to obtain binomial confidence intervals. All this should be stated in the analysis section after methods or within the methods section.</p><p>There were a lot of baseline questionnaires collected but only a selection of variables have been presented in Table 1, for an example education, occupation, marital status, socio-economic status, as the readers gain more understanding of the characteristics of individuals who are identified as high risk for HIV infections. These categories could be grouped into sensible groups ofcourse. These variables can added as an additional table in the manuscript.</p><p>Table 1: The variables &#x0201c;Daily wage (2017 US Dollars): mean&#x0201d;, please include SDs as well.</p><p>**********</p><p>7. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy">Privacy Policy</ext-link>.</p><p>Reviewer #3: No</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" xlink:href="https://pacev2.apexcovantage.com/">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p></body></sub-article><sub-article id="pone.0233600.r006" article-type="author-comment"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0233600.r006</article-id><title-group><article-title>Author response to Decision Letter 2</article-title></title-group><related-article id="rel-obj006" ext-link-type="doi" xlink:href="10.1371/journal.pone.0233600" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>3</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">6 May 2020</named-content>
</p><p>Response to Reviewers &#x00026; Editor</p><p>Title: A pilot randomized trial of incentive strategies to promote HIV retesting</p><p>Manuscript: PONE-D-19-27665</p><p>Response to Reviewers&#x02019; Comments</p><p>Reviewer #3</p><p>General Comments:</p><p>This is a very interesting study assessing the feasibility and acceptability of various incentive strategies, including commitment contracts that required a baseline deposit, to promote HIV retesting among at-risk adults in rural Uganda. Some minor comments considered important.</p><p>Specific Comments:</p><p>Although the methods sections is well detailed, the authors have not explicitly included a statistical analysis section. For example descriptive statistics presented as means(SD), median(IQR) and counts(%ages), also the authors have presented proportions with 95%CI using exact methods to obtain binomial confidence intervals. All this should be stated in the analysis section after methods or within the methods section.</p><p>Response: We have revised the methods section to include a statistical analysis section (under a subheading within the Methods section), including additional detail about the statistical analyses performed for this study. </p><p>There were a lot of baseline questionnaires collected but only a selection of variables have been presented in Table 1, for an example education, occupation, marital status, socio-economic status, as the readers gain more understanding of the characteristics of individuals who are identified as high risk for HIV infections. These categories could be grouped into sensible groups of course. These variables can added as an additional table in the manuscript.</p><p>Response: We now include baseline education and marital status in Table 1, and socio-economic status is included as mean daily wage. </p><p>Table 1: The variables &#x0201c;Daily wage (2017 US Dollars): mean&#x0201d;, please include SDs as well.</p><p>Response: We now included standard deviations for these resulted variables.</p><supplementary-material content-type="local-data" id="pone.0233600.s006"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers Retest Pilot v21Apr2020.docx</named-content></p></caption><media xlink:href="pone.0233600.s006.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></body></sub-article><sub-article id="pone.0233600.r007" article-type="editor-report"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0233600.r007</article-id><title-group><article-title>Decision Letter 3</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>De Socio</surname><given-names>Giuseppe Vittorio</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2020 Giuseppe Vittorio De Socio</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Giuseppe Vittorio De Socio</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article id="rel-obj007" ext-link-type="doi" xlink:href="10.1371/journal.pone.0233600" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>3</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">11 May 2020</named-content>
</p><p>A pilot randomized trial of incentive strategies to promote HIV retesting in rural Uganda</p><p>PONE-D-19-27665R3</p><p>Dear Dr. Chamie,</p><p>We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.</p><p>Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.</p><p>Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/">https://www.editorialmanager.com/pone/</ext-link>, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p><p>If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p><p>With kind regards,</p><p>Giuseppe Vittorio De Socio, MD, PhD</p><p>Academic Editor</p><p>PLOS ONE</p><p>Additional Editor Comments (optional):</p><p>Reviewers' comments:</p></body></sub-article><sub-article id="pone.0233600.r008" article-type="editor-report"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0233600.r008</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>De Socio</surname><given-names>Giuseppe Vittorio</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2020 Giuseppe Vittorio De Socio</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Giuseppe Vittorio De Socio</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article id="rel-obj008" ext-link-type="doi" xlink:href="10.1371/journal.pone.0233600" related-article-type="reviewed-article"/></front-stub><body><p>
<named-content content-type="letter-date">20 May 2020</named-content>
</p><p>PONE-D-19-27665R3 </p><p>A pilot randomized trial of incentive strategies to promote HIV retesting in rural Uganda </p><p>Dear Dr. Chamie:</p><p>I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p><p>If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email>onepress@plos.org</email>.</p><p>For any other questions or concerns, please email <email>plosone@plos.org</email>. </p><p>Thank you for submitting your work to PLOS ONE.</p><p>With kind regards,</p><p>PLOS ONE Editorial Office Staff</p><p>on behalf of</p><p>Dr. Giuseppe Vittorio De Socio </p><p>Academic Editor</p><p>PLOS ONE</p></body></sub-article></article>